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Background
Pancreatic cancer is the eighth most common
cancer in the UK and the sixth most common
cause of cancer death; in 1998, 3198 men and 
3364 women died from this condition. In an
average health authority with a population of
500,000, there would be approximately 60 new
cases of pancreatic cancer per year, based on the
age and sex distribution of England and Wales.
Over 75% of these patients are over 65 years 
of age.
The symptoms are wide ranging, but they 
may appear only towards the latter stage of the
disease, so the vast majority of patients present 
with advanced disease. There are therefore rarely
more than a few months between diagnosis and
death, and palliative care is the best treatment 
that can be offered for the majority of sufferers. 
It is estimated that around 10–15% of patients
diagnosed with pancreatic cancer currently 
receive palliative chemotherapy. This proportion 
is expected to rise and may increase to around 
35% within the next few years.
5-Fluorouracil (5-FU) has been the standard
chemotherapy used for pancreatic cancer in 
the UK over recent years, with evidence of a 
small survival advantage and improvement in
quality of life (QoL) in a proportion of these
patients. Gemcitabine is a relatively new
chemotherapy drug; it inhibits DNA synthesis 
and is indicated for the treatment of adults with
locally advanced or metastatic adenocarcinoma 
of the pancreas and for patients with 5-FU
refractory pancreatic cancer.
Objectives
This review aimed to evaluate the clinical and cost-
effectiveness of gemcitabine as first and second
line therapy in the treatment of pancreatic cancer.
Methods
Systematic searches of clinical effectiveness, cost-
effectiveness, and modelling in pancreatic cancer
and gemcitabine were performed. The databases
searched included: MEDLINE, EMBASE, Science
Citation Index, Database of Abstracts of Reviews 
of Effectiveness, NHS Economic Evaluation
Database and the National Research Register. 
Web resources and industry submissions were also
consulted. All HTA and related secondary research
studies were included. Primary research studies
were included if the authors had attempted to
measure an outcome of importance.
A qualitative review was undertaken of all
identified studies conducted on patients with a
diagnosis of pancreatic adenocarcinoma, using
gemcitabine alone or in combination with another
drug. All Phase I studies were excluded.
Cost-effectiveness analyses were performed to
estimate the marginal cost and marginal effective-
ness of gemcitabine in comparison with standard
therapy with 5-FU. The difference in mean survival
was combined with the difference in the average
cost of the interventions to calculate the cost per
life-year gained (LYG). Costs were direct drug 
costs and health service costs. No QoL data were
identified. However, given the significance of 
QoL for patients with pancreatic cancer, an
illustration was provided, using quality-adjusted
time without symptoms or toxicity (Q-TWiST)
analysis, of the potential impact of QoL on 
the cost per LYG results.
Results
Number and quality of studies,
and direction of evidence of 
clinical effectiveness
A review of the published literature identified
seven randomised controlled trials (RCTs).
However, only one was a fully published 
RCT comparing gemcitabine with standard
chemotherapy treatment (5-FU). No RCTs 
of gemcitabine versus best supportive care 
were located. Fifty-seven other studies were
identified, of which 17 examined the use of
gemcitabine alone.
No high-quality RCTs of gemcitabine as a second
line treatment were identified.
Executive summaryExecutive summary
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Summary of benefits
There is a very poor evidence base by which to
assess the efficacy of gemcitabine. The validity 
of the only RCT that compared gemcitabine 
with the standard treatment of 5-FU is open to
question. In the control arm of this study the 
drug was administered as a bolus infusion. It is
unlikely that bolus 5-FU alone would be used as
standard practice in the UK. In other forms of
gastrointestinal cancer therapy, bolus 5-FU alone
would be considered to be inferior to other 5-FU
regimens in terms of response rates and efficacy.
These factors, in combination with the small
patient sample included in the trial, mean that 
its results cannot be regarded as definitive.
From the available evidence it would appear that
gemcitabine as a first line therapy offers similar
survival to 5-FU-based regimens, but it is impossible
to demonstrate conclusively its superiority in terms
of either survival or QoL.
There is insufficient evidence to determine with
any degree of certainty the benefit of gemcitabine
as a second line therapy.
Costs
No published UK costings of gemcitabine were
identified. The cost of 5-FU is dependent on 
the mode of its delivery. Two regimens currently
used in the UK are considered: the De Gramont
regimen (5-FU 400 mg/m
2 by bolus injection plus
400 mg/m
2 22-hour infusion, plus 200 mg/m
2
folinic acid 2-hour infusion for 2 days at 14-day
intervals) for which an inpatient stay is generally
required for its administration; and protracted
venous infusion of 5-FU (300 mg/m
2 per day via 
an ambulatory pump), which allows the drug to 
be administered in the home setting. Although 
the drug cost of gemcitabine is more expensive
that 5-FU this may be partly offset by lower
administration costs, particularly in comparison
with the De Gramont regimen. The cost of drug
administration for protracted venous infusion 5-FU
varies markedly according to local circumstances.
For instance, the frequency of visits to the hospital
for checking and flushing of the central line and
pump may vary between once weekly and once
every 6 weeks. This type of local variability will
impact on the cost of 5-FU and, therefore, on 
the relative cost-effectiveness of gemcitabine.
Costs per life-year gained
Preliminary estimates of the cost of gemcitabine
per LYG suggest that it may be below £20,000.
However, the clinical evidence on which the
analysis is based is poor and no published UK
estimates of the cost of gemcitabine have been
identified. The sensitivity analysis confirms that 
the cost per LYG is sensitive to assumptions on 
cost and survival. Given these uncertainties, it
would be difficult to place too much weight on 
the findings. Further evidence is required before
any definite conclusions can be drawn about 
cost-effectiveness.
Cost per quality-adjusted life-year
Given the significance of QoL for patients with
pancreatic cancer an illustration has been pro-
vided, using Q-TWiST analysis of the potential
impact of QoL adjustments on survival and the 
cost per LYG. No QoL data were identified, so 
the results of the analysis are purely illustrative.
However, the analysis does demonstrate that the
addition of a QoL adjustment is likely to reduce
the survival gain. This would result in a cost per
quality-adjusted life-year gained that is higher 
than the cost per LYG.
Conclusions
Need for further research
Gemcitabine as first line therapy
Until Phase II studies with existing or new drugs,
alone or in combination, demonstrate significant
improved benefit in pancreatic cancer, randomised
studies are likely to be directed towards toxicity,
QoL and any small survival benefits that may be
obtained with gemcitabine alone compared with 
a modern 5-FU-based protocol or a combination 
of the two.
The evidence for QoL benefits of gemcitabine 
is particularly poor. There is widespread acknow-
ledgement of the need for a RCT to confirm the
survival benefits of gemcitabine and, particularly,
to enable the collation of acceptable QoL data.
Gemcitabine as second line therapy
Further high-quality randomised trial evidence 
is required to determine fully the value of
gemcitabine as a second line treatment.Health Technology Assessment 2001; Vol. 5: No. 24
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P
ancreatic cancer is the eighth most common
cancer in the UK and the sixth most common
cause of cancer death. One-year survival rates are
in the order of 12% and less than 2% of patients
survive to 5 years.
1 In 1998, 3198 men and 3364
women died from pancreatic cancer in the UK and
it is estimated that about 7000 new diagnoses are
made annually.
2
The symptoms of pancreatic cancer are wide-
ranging, and quality of life (QoL) can be greatly
reduced by jaundice, nausea, weight loss, loss of
appetite and severe pain; patients may also suffer
from diabetes, diarrhoea and profound depression.
These symptoms may appear only towards the latter
stages of the illness, so the majority of patients
present with advanced stage disease. As such, 
there are rarely more than a few months between
diagnosis and death, and palliative care is the best
that can be offered for the majority of sufferers.
Description of the underlying
health problem
Epidemiology
Pancreatic cancer has an annual incidence rate 
of around 12 per 100,000 and a similar 11 per
100,000 mortality rate in England and Wales.
1
In 1997 there were an estimated 5730 people
(2740 males and 2990 females) diagnosed with
pancreatic cancer in England and Wales.
3 Of these,
4320 (1940 males and 2380 females) were in the
over 65 years age group, accounting for 75% of 
all patients diagnosed with pancreatic cancer 
(Figure 1
4).
In an average health authority with a population 
of 500,000, there would be approximately 60 new
cases of pancreatic cancer per year, based on the
age distribution in England and Wales.
The most consistent risk factor is smoking,
5
but diet
6 (particularly the lack of fruit and vege-
tables or excess alcohol) has also been implicated.
Diabetes and pancreatitis are additional risk factors
and a very small number of tumours have been
shown to be familial.
The 1-year survival rates are generally low at around
12%
1 and survival to 5 years is extremely rare, at
less than 3%.
1 Therefore, as a group, patients with
pancreatic cancer have an extremely poor prognosis
when considered within the context of other
cancers. The disease often presents late, which
contributes to the poor outlook. The stage of
Chapter 1
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FIGURE 1 National age/sex registrations for pancreatic cancer, 1994 (Source: Office for National Statistics
4) (   , men; , women)Background to the disease
2
disease is determined by the tumour–node–metastasis
(TNM) staging system, as shown below in Table 1
7;
although only US data are available, they show
clearly that the highest proportion of patients are
defined as having Stage IV tumours.
Currently, curative surgery is offered to only about
4% of the overall patient population.
1 Survival
rates are highest in this patient group and some
specialist centres attain 21% 5-year survival rates.
8
In the latter stages of the disease, palliative surgery,
stenting, chemotherapy or radiotherapy can be
used to relieve symptoms, but such treatments are
purely palliative and outcomes remain poor.
Current service provision
The majority of patients diagnosed with pancreatic
cancer receive no definitive treatment. Historically,
curative surgery has been a hazardous procedure,
commonly with perioperative 30-day mortality rates
of over 10%. New guidance on the management 
of upper gastrointestinal (GI) cancers has recom-
mended that surgery should be carried out only by
specialists in cancer centres, where perioperative
30-day mortality rates should rarely exceed 5%.
9
For the majority of those with late stage disease,
the treatments offered are palliative. Although
radiotherapy and chemoradiotherapy may both be
considered for young, fit patients with inoperable
localised disease, palliative treatment is largely
based on best supportive care (BSC) or systemic
chemotherapy to improve the patient’s QoL. 
Other techniques used include the insertion of
biliary stents and surgical bypasses.
The fact that over 75% of these patients are over
65 years of age
9 has important functional implica-
tions for the suitability of treatments available
because individuals may be of poor performance
status and have other co-existing illnesses. Active
therapy may, therefore, be unsuitable and BSC is
frequently the only treatment offered.
Bachmann presented data on treatment patterns
for patients diagnosed with pancreatic cancer 
in the south and west of England and in South
Wales between June 1996 and May 1997.
10 Based
on data from 36 hospitals, 6% of patients underwent
surgery, 7% received chemotherapy alone, and 
less than 5% had chemoradiotherapy or radio-
therapy. The majority of patients, around 80%,
received BSC.
The use of chemotherapy varies by geographical
location and between different providers. No data
are available to allow the accurate determination 
of the current proportion of patients receiving
palliative chemotherapy on a national basis. It is
likely to have increased since Bachmann’s study,
10
but is estimated to be around 10–15% by a number
of leading clinicians (Crellin A, Yorkshire Centre
for Clinical Oncology, Cookridge Hospital, Leeds:
personal communication, 2000). Eli Lilly have
estimated the figure to be 24%, which is quoted 
in their submission.
11
Following the introduction of new guidance on 
the management of upper GI cancers,
9 in which
chemotherapy has been recommended as a con-
sideration in both first line and adjuvant therapy, 
it is anticipated that an increasing percentage of
patients will receive this in the next few years. The
proportion of patients receiving chemotherapy
may rise to around 35%. This is based on the
assumption that 10–15% of patients may undergo
surgical resection in the future. Of the remaining
85–90%, it is assumed that 40% will be suitable 
for palliative chemotherapy.
5-Fluorouracil (5-FU) has been the standard
chemotherapy used for pancreatic cancer in the
UK. There is evidence of a small survival advantage
and an improvement in QoL in some patients.
12
5-FU has been studied using a variety of doses and
schedules, but the response rate rarely exceeds
20% and no consistent effect on disease-related
symptoms or survival has been demonstrated.
13
Gemcitabine (Gemzar) is now used variably in 
TABLE 1  Stage of cancer at presentation (source:American College of Surgeons National Cancer Database
7)
Stage Definition (from TNM staging system) Approximate %
at diagnosis
I No distant metastases or regional lymph nodes present; the tumour is either limited to the pancreas 
or has extended directly to the duodenum, bile duct or peripancreatic tissues 21
II No distant metastases or regional lymph nodes present, but the tumour has extended directly to the stomach,
spleen, colon or adjacent large blood vessels 10
III Regional lymph node metastases are present but no distant metastases; tumour stage is immaterial 17
IV Distant metastases present; tumour and lymph node stage are immaterial 52Health Technology Assessment 2001; Vol. 5: No. 24
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the UK but there remains uncertainty about the
role of chemotherapy in pancreatic cancer and 
the optimal regimen.
The number of patients currently receiving
gemcitabine for pancreatic cancer is not known.
Eli Lilly have estimated that 417 patients, 6% of
those diagnosed, will receive gemcitabine in the
UK in 2000.
11 This is derived from the assumptions
that 24% of patients diagnosed with pancreatic
cancer will receive chemotherapy and that 29% 
of these patients currently receive gemcitabine. 
It is not possible to check the reliability of 
this figure.
Description of intervention
Gemcitabine is a chemotherapy drug that inhibits
DNA synthesis. It is a novel nucleoside analogue
with a wide spectrum of activity against a variety of
solid tumours. Although many clinical trials have
evaluated gemcitabine in different regimens and
doses, only one randomised controlled trial (RCT)
has compared it with 5-FU as a first line treatment.
13
Based on the results of this trial, which showed
improved clinical benefit and a median survival
improvement, gemcitabine has been adopted 
in the USA as the standard palliative chemo-
therapy for advanced pancreatic cancer.
14
Identification of patients
Patients should be identified by following the
recommendations from the guidance in the manage-
ment of upper GI cancers,
9 as detailed below.
Patients with jaundice, or those aged over 55 years
who have pain or other symptoms that could be
due to pancreatic cancer, should be assessed by
abdominal ultrasound.
9 Those with dilated bile
ducts and no evidence of gallstones, and any 
others considered likely to have pancreatic 
cancer on the basis of symptoms and ultrasound
findings, should normally be referred for 
further assessment.
Further assessment of the tumour may involve
spiral computed tomographic scanning, endoscopic
ultrasound, magnetic resonance cholangio-
pancreatography, and/or endoscopic retrograde
cholangiopancreatography. When symptoms or
imaging clearly show that the disease is metastatic
or inoperable, or the patient is not sufficiently fit 
to undergo radical treatment, there may be no
advantage in further assessment of the primary
tumour. Such patients should be offered appro-
priate palliative treatment.
Criteria for treatment
Chemotherapy, including gemcitabine, should be
administered only to patients with a reasonably
good performance status. A decision to offer this
agent should be based on the stage of the disease
(if known), age, prognosis, performance status,
liver function and haematological status, and a
general assessment of the patient’s well-being.
Intervention
The following descriptions have been taken from
the ‘summary of product characteristics’, as listed
in the electronic Medicines Compendium.
15
Therapeutic classification
Gemcitabine is indicated for the treatment of 
adult patients with locally advanced or metastatic
adenocarcinoma of the pancreas, and for those
with 5-FU refractory pancreatic cancer.
Dosage form and route
In adults, the recommended dose of gemcitabine 
is 1000 mg/m
2, administered by a 30-minute
intravenous infusion. This should be repeated once
weekly for up to 7 weeks, followed by a week of
rest. Subsequent cycles should consist of infusions,
once weekly, for 3 consecutive weeks out of every 
4 weeks. A dose reduction is applied based on the
degree of toxicity experienced by the patient.
Contraindications
Gemcitabine is contraindicated in those patients
with a known hypersensitivity to the drug.
Warnings
Prolongation of the infusion time and increased
dosing frequency have been shown to increase
toxicity. Gemcitabine can suppress bone marrow
function, as manifested by leucopenia, thrombo-
cytopenia and anaemia. However, myelosup-
pression is short lived, not usually resulting in dose
reductions and only rarely causing discontinuation.
Administration of this agent should be stopped at
the first signs of any evidence of microangiopathic
haemolytic anaemia, such as a rapidly falling
haemoglobin level with concomitant thrombo-
cytopenia or elevation of serum bilirubin, serum
creatinine, blood urea nitrogen or lactate dehydro-
genase, which may indicate development of the
haemolytic uraemic syndrome. Renal failure may
not be reversible, even with the discontinuation 
of therapy, and dialysis may be required.
Precautions
The status of patients receiving therapy with
gemcitabine must be monitored closely and
suitable laboratory facilities are required.Background to the disease
4
Treatment may be necessary for patients who are
compromised by drug toxicity.
Therapy should be started cautiously in those 
with compromised bone marrow function. As with
other oncolytics, the possibility of cumulative bone
marrow suppression should be considered when
using combination or sequential chemotherapy.
Patients receiving gemcitabine should be 
monitored prior to each dose for platelet,
leucocyte and granulocyte counts. The 
suspension or modification of therapy should 
be considered when drug-induced marrow
depression is detected. Peripheral blood 
counts may continue to fall after gemcitabine 
is stopped.Health Technology Assessment 2001; Vol. 5: No. 24
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Methods for reviewing effectiveness
Search strategy
The search strategy aimed to identify all publications
relating to gemcitabine and pancreatic cancer.
Keyword strategies were developed using key
references retrieved through initial scoping searches.
Search strategies did not include search terms or
filters that would limit results to specific publication
types or study designs. Date and language restrictions
were not used. Searches of the following databases
were undertaken: MEDLINE, EMBASE, Science
Citation Index, Cochrane Database of Systematic
Reviews (CDSR), Central Cochrane Controlled
Trials Register (CENTRAL/CCTR), the NHS
Centre for Reviews and Dissemination (CRD)
databases (Database of Abstracts of Reviews of
Effectiveness (DARE), NHS Economic Evaluation
Database (NHS EED), HTA), and the Office of
Health Economics (OHE) Health Economics
Evaluation Database (HEED). A search of the last 6
months of PubMed was undertaken to identify
recent studies not yet indexed on MEDLINE.
In addition to searches of electronic bibliographic
databases, further sources were consulted to
identify current research and grey literature. 
The National Research Register, Medical Research
Council Clinical Trials Register, US National
Institutes of Health Clinical Trials Register, and
Current Research in Britain databases were
searched. The publications lists and current
research registers of health technology assessment
and guideline-producing agencies, and funding
and regulatory bodies were consulted. Industry
submissions and the reference lists of included
studies were handsearched and the Science
Citation Index search facility was utilised.
Preliminary scoping searches were completed in
July 2000. Full searches of bibliographic databases,
and of further current research and grey literature
sources, were carried out in August 2000. 
Hand and citation searches were undertaken in
November 2000. The search strategies and sources
consulted are listed in appendix 1.
Inclusion and exclusion criteria
•S tudies conducted on patients with a diagnosis
of pancreatic adenocarcinoma were considered.
•S tudies involving the administration of gemcita-
bine to patients with inoperable advanced
(including locally advanced and metastatic) or
relapsed disease, and as an adjuvant treatment
for curatively resected pancreatic disease with 
no apparent residual disease, were considered.
•A ll studies that used gemcitabine alone or in
combination with another drug were considered.
•A ll Phase I studies were excluded.
Data extraction strategy
Data were extracted by one reviewer, using
standardised forms (appendix 2), and were
checked by a second reviewer. All disagreements
were resolved by discussion.
Quality assessment strategy
All publications were assessed according to the
accepted hierarchy of evidence,
16 whereby meta-
analyses of RCTs were taken to be the most author-
itative form and uncontrolled observational studies
the least authoritative. In addition, the Jadad scoring
system was used to assess the quality of all RCTs
and the resulting quality scores are listed (Table 2).
Data synthesis
Given the heterogeneity of the interventions
evaluated and of the study population character-
istics and outcome measures, we have not
attempted to pool outcomes or conduct any 
form of meta-analysis. Instead, a qualitative 
analysis was undertaken. 
Results
Quantity and quality of research
available
Number of studies identified
The searches undertaken retrieved a total of 
458 studies. These included seven RCTs, 57 Phase
II studies and 33 Phase I studies. In addition, we
identified one investigational new drug treatment
study and two retrospective and four prospective
clinical studies. All Phase I trials were excluded
from this assessment.
Randomised controlled trials
Seven RCTs were identified.
13,17–22 The character-
istics of their design are shown in Table 2. Two
Chapter 2
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studies compared the role of gemcitabine in 
the adjuvant setting in combination with both
chemotherapeutic and immunotherapeutic 
drugs. One compared the effect of gemcitabine
with that of bolus infusional 5-FU and another
compared gemcitabine with 5-FU administered
intra-arterially. Three further trials compared
gemcitabine with metallomatrix proteinase
inhibitors; two of these studies involved 
marimistat and one BAY12-9566.
The RCT published by Burris and colleagues in
1997
13 compared the effect of gemcitabine with 
5-FU in patients with pathologically confirmed
locally advanced or metastatic pancreatic cancer.
No description of the method of randomisation
was available and the investigation was single blind.
Drop-outs and withdrawals were described.
Two trials were published by Lygidakis and 
co-workers.
19,20 These compared the use of
neoadjuvant and adjuvant gemcitabine in
combination with immunotherapy with surgery
alone. The first examined the use of gemcitabine
in the adjuvant setting.
19 No descriptions of
randomisation and blinding were available, 
but the authors accounted for all withdrawals 
and drop-outs. The other study examined the 
use of a chemoimmunotherapy regimen involving
gemcitabine as both a neoadjuvant and an
adjuvant treatment.
20 No descriptions were
available of the methods involved in random-
isation and blinding, and there was no mention 
of withdrawals and drop-outs.
The remaining four studies were available only in
summary form and, consequently, our assessment
of quality was not necessarily fully representative 
of the actual study design owing to the limited
methodological details available.
Two of these RCTs were conducted by British
Biotech and compared the use of gemcitabine 
with the matrix metalloproteinase inhibitor
marimistat. The results of the earliest of 
these trials (study 128) were published, in 
abstract, at the year 2000 annual meeting of the
American Society of Clinical Oncology (ASCO),
and further details are available from a company
press release.
21 However, no details are provided
about the methods used for randomisation,
blinding, or withdrawals and drop-outs. The only
details relating to the second study are available
from a press release.
17 Again, no description of
randomisation is available and there is no
discussion about withdrawals and drop-outs.
However, the study is described as double blind
and placebo controlled.
A further RCT, conducted by Moore and
colleagues,
22 compared gemcitabine with 
another matrix metalloproteinase inhibitor 
known as BAY12-9566. Again, the results of 
this study have been published only in abstract
form, so full methodological details are not
available. No information was given relating to
randomisation and blinding, or to withdrawals 
and drop-outs.
The final RCT identified is currently ongoing and
is being conducted by Cantore and co-workers.
18
Preliminary findings were, again, presented at
ASCO 2000 and an abstract is available. Although
drop-outs and withdrawals were described, no
account of the methods of randomisation or
blinding was supplied.
TABLE 2  Description of RCTs identified
Study Was the Was the method Was the Was the method Was there a Jadad
study used in  study described used for blinding description of score
described randomisation as  double considered withdrawals
as random- considered blind? appropriate? and drop-outs?
ised? appropriate?
Burris et al., 1997
13 Yes Not described No Not described Yes 2
Lygidakis et al., 1988
20 No Not described No Not described Yes 1
Lygidakis et al., 1988
19 Yes Not described No Not described Yes 2
Cantore et al.,, 2000
18 Yes Not described No Not described No 1
Moore et al., 2000
22 Yes Not described No Not described No 1
Rosemurgy et al., 1999
21 Yes Not described Yes Not described No 2
(British Biotech study 128)
British Biotech, 2000  Yes Not described Yes Not described No 2
(study 193)
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Other identified studies
We also identified a total of 57 Phase II studies 
and seven of other design. Seventeen examined the
use of gemcitabine alone.
23–39 A further 18 looked
at the drug in combination with 5-FU.
40–57 Five
studies combined gemcitabine with docetaxel,
58–62
four with platinum compounds,
63–66 two with
mitomycin C (MMC),
67,68 and seven with other
drugs in more complex combinations.
69–75 In
addition, four examined the role of gemcitabine
plus radiation,
76–79 and two used regimens 
in which gemcitabine was combined with
hormonal treatments.
80,81
The characteristics of all studies are given in
appendix 3 (Tables 3–12). The key results from the
studies are also given in appendix 3 (Tables 13–22).
Discussion of results
Survival
Gemcitabine as an adjuvant treatment
The evidence identified relating to the use of
gemcitabine as an adjuvant treatment consists of
two RCTs. Both were published by Lygidakis and
colleagues and examined the use of gemcitabine 
as part of a combination chemoimmunotherapy
regimen. In the first study,
19 involving 512 patients
recruited between 1991 and 1998, those random-
ised to adjuvant chemotherapy achieved a better
mean survival (32 months with curative intent 
and 16 months with palliative surgery) than those
who received surgery alone (14 months with
curative intent and 6.8 months with palliative
surgery). In the second study
20 (n = 26), in which
the chemoimmunotherapy was administered as
both a neoadjuvant and an adjuvant treatment,
there was a statistically significant difference in 
the number of patients with progressive disease
and in survival. Three patients who received the
multi-modality treatment compared with nine who
received surgery alone had progressive disease 
(p < 0.01) and, at the time the study was written, 
all 14 patients in the chemoimmunotherapy 
group remained alive, compared with only 
six in the surgery alone group (p < 0.01).
A number of limitations affect these two studies.
First, both obtained low Jadad scores; their results,
therefore, can be considered to be of low quality.
In addition, it was difficult to distinguish between
the effects of the large number of different drugs
administered and, consequently, to state definitively
the value of gemcitabine in the adjuvant setting. 
As such, the evidence identified relating to this use
of gemcitabine is limited.
20 In addition, no Phase II
or other studies were identified that could further
establish the effectiveness of this drug in the
adjuvant setting.
Gemcitabine as a single agent therapy
The best available evidence relating to the use of
gemcitabine as a first line therapy comes from
Burris and co-workers.
13 This study compared 
the use of gemcitabine with 5-FU in 126 patients
with locally advanced or metastatic pancreatic
cancer. Patients randomised to gemcitabine had
significantly better 1-year survival (18% versus 
2%, p = 0.0025), significantly better median
survival (5.65 versus 4.41 months, p = 0.0025),
improved median progression-free survival 
(2.33 versus 0.92 months, p = 0.0002), and a 
longer time to treatment failure (2.04 versus 
0.92 months, p = 0.0004). However, no difference
was observed in partial tumour response rates
between the two treatment arms.
Although this study did show a significant benefit
for the use of gemcitabine in comparison with 
5-FU, questions exist that cast doubt on the validity
of its results. First, in the control arm, 5-FU was
administered as a bolus infusion. This method has
been shown to be suboptimal in other types of GI
cancers
82 and, as such, may not be a valid control
against which to evaluate gemcitabine. Other
randomised studies that have compared the use of
5-FU against BSC for pancreatic cancer have used
more clinically active regimens and have shown
similar survival rates to that obtained by gemcita-
bine in the Burris trial.
12,83 It could therefore be
surmised that, had 5-FU been given in a more
active form, the comparatively significant benefit
attributed to gemcitabine could have been reduced.
Secondly, this particular trial obtained a low Jadad
score. Finally, it can be criticised because of the small
sample size involved. Only 126 individuals were
included in the analysis; results based on such a small
patient population cannot be regarded as definitive.
This, the best quality data available, fails adequately
to prove the superiority of gemcitabine in first line
treatment, so it is necessary to examine other 
data. The additional RCTs identified all assessed
gemcitabine against experimental treatments, so
their results are difficult to extrapolate into this
argument. The published information relating to
the two British Biotech RCTs is limited. Both of
these trials were reasonably large, with study 128
21
recruiting 414 and study 193
17 239 patients.
Although we know that no significant difference 
in survival was observed between marimistat and
gemcitabine, we have been unable to obtain any
details of survival times in either arm. In addition,Effectiveness
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the reports available consist of abstracts and 
press releases only and, as such, the information
available is insufficient to enable us to comment 
on the effectiveness of gemcitabine.
In the abstract published by Moore and colleagues,
22
details are given of a randomised comparison of
gemcitabine and BAY12-9566. In a trial involving
277 patients, gemcitabine proved to produce
statistically significant better survival than BAY12-
9566, with a median survival rate of 6.4 months
compared with 3.2 (p = 0.0001) and a median
progression-free survival of 3.54 months compared
with 1.77 (p = 0.012). This median survival rate is
broadly comparable with the 5.65 months obtained
by Burris and co-workers.
Eli Lilly have suggested that BAY 12-9566 was used
in this RCT at a dosage that was ineffectual. No
response appeared to be seen in this arm and
toxicity was minimal. It has been claimed by Eli
Lilly,
11 therefore, that this trial was equivalent to
gemcitabine against BSC. However, Phase I and II
studies were conducted, prior to this RCT, to
determine the active and optimum dose of 
BAY 12-9566.
84 The dosage determined by these
earlier studies was used in this RCT. In addition,
while BAY 12-9566 may have exerted no effect in
this trial, it is also possible that it may have
demonstrated a negative survival impact. It would
therefore be inappropriate to extrapolate the
results as a study of gemcitabine against BSC. 
It should also be noted that the abstract reports
only the interim analysis, so further details are
required before a full assessment of this RCT 
can be made.
One retrospective report of an investigational new
drug treatment programme, published by
Storniolo and colleagues, was identified.
33 This
study had on open-label single-arm design and
gathered data from 3023 patients with advanced
pancreatic cancer treated at 823 centres. The data
collected were used to assess several outcomes, 
but the number of observations for any given 
end-point varied according to the number of
completed records returned by the investigators.
As such, patient numbers vary according to the
specific data point in question. Full details of the
numbers assessed are listed in Table 5.
Storniolo and co-workers reported median survival
to be 4.8 months (95% confidence interval (CI),
4.5 to 5.1), the probability of survival at 1 year 
to be 15%, and the median time to disease
progression to be 2.7 months (95% CI, 2.6 to 2.7).
Tumour response was assessed in 982 patients.
Within this patient group, 1.4% achieved a
complete response and 10.6% a partial response;
there was an overall response rate of 12.0% 
(95% CI, 10.0 to 14.2).
All the remaining studies identified were of a
Phase II or retrospective cohort design. Ten were
published in abstract form,
23,25,26,28,30–32,34,36,39 so 
the available data are limited. In addition, they
frequently included only very small numbers of
participants, often reduced further by a failure to
evaluate all patients. A large number of different
outcomes were reported and, owing to the nature
of study designs and differences in patient popula-
tions between studies, the results were not fully
comparable. We have therefore not attempted to
pool outcomes. However, from these studies, 1-year
survival ranged between 4% and 26%, and median
survival between 4 months and 8.8 months.
Although it would appear from this information
that gemcitabine is a reasonable treatment method
for patients with advanced pancreatic cancer, in
the light of other available research it fails to prove
an absolute advantage over other treatment
options, such as 5-FU. In two RCTs
12,83 comparing
5-FU to BSC in patients with advanced pancreatic
cancer, comparable results have been obtained.
Glimelius and colleagues
12 and Palmer and co-
workers
83 reported median survivals of 6 and 
8.25 months, respectively, in patients receiving 
5-FU-based chemotherapy, compared with 2.5 and
3.75 months in patients who received BSC. The
administration of gemcitabine led to a median
survival of 5.65 months in the Burris trial,
13
6.4 months in the Moore trial,
22 and ranged
between 4 months and 8.8 months in the 
other identified studies, so no distinct survival
benefit of gemcitabine over other forms of
chemotherapy can be claimed.
Gemcitabine in combination chemotherapy
A total of 36 Phase II studies were identified that
had utilised gemcitabine in combination with
another chemotherapeutic drug. 5-FU was the
most frequent combination (used in 18 studies)
and, with this regimen, 1-year survival was seen 
to range between 25% and 39.5%, and median
survival between 4.4 months and 13 months. 
There were far fewer Phase II studies examining
other gemcitabine combinations, and the results
and outcomes are not consistently reported. 
All the study details are, however, presented 
in Tables 6–10 and 16–20 (appendix 3).
Based on the results of the Phase II studies, it is
impossible to assess fully the impact of gemcitabineHealth Technology Assessment 2001; Vol. 5: No. 24
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on survival as part of a combination chemotherapy
regimen. Most of the results were published as
abstracts and the data were inconsistently reported.
In addition, the numbers of participants entering
these studies were very small and the numbers
evaluated were, frequently, even smaller. It was
therefore very difficult to assess any trends that
may exist in survival, median progression-free
survival, or response rates. Although it would
appear, from the limited details available, that 
the administration of such regimens is reasonable,
further studies and randomised trials are necessary
before the value of gemcitabine in combination
chemotherapy can be properly ascertained.
Gemcitabine in chemoradiation
Only four Phase II studies
76–79 were identified 
that examined the role of gemcitabine in chemo-
radiation. All were published in abstract form.
They reported different outcomes and were 
very small projects in terms of the numbers of
patients enrolled and assessed. Full details of 
study designs and results are shown in Tables 11
and 21 (appendix 3), but, based on the infor-
mation available, there is insufficient evidence to
assess the effect of gemcitabine on survival when
administered as part of a chemoradiation regimen.
Further, detailed, high-quality studies are required
before this role can be fully determined.
Gemcitabine and hormonal treatment
Two Phase II studies
80,81 were identified that
examined the efficacy of gemcitabine in combina-
tion with hormonal agents. Details are listed in
Tables 12 and 22 (appendix 3). Both of these
studies are small and differ in the drugs used and
outcomes assessed. As such, in our opinion, there
is insufficient evidence to determine the role of
gemcitabine in combination with hormonal agents
Gemcitabine as a second line treatment
Eight of the identified studies involved participants
with relapsed disease.
27,29,35,38,40,46,68,79 None of the
relevant studies was a high-quality RCT. Rothenberg
and colleagues’ trial
29 was the only one exclusively
to involve individuals with relapsed disease and
examined the effect of gemcitabine in patients
with metastatic pancreatic cancer that had pro-
gressed despite the administration of 5-FU. This
study demonstrated a median survival of 4 months
and a 1-year survival of 4%. Only 74 patients were
recruited, and, of these, only 63 were evaluated 
for clinical benefit response ((CBR) see ‘Quality 
of life’ section below) and 54 for response. The
remaining studies all involved relapsed patients 
as only a small part of the patient cohort, so 
the extrapolation of their results to assess the
effectiveness of gemcitabine as a second line
treatment is difficult. Three involved the adminis-
tration of gemcitabine alone,
27,35,38 two gemcitabine
in combination with 5-FU,
40,46 one gemcitabine and
MMC,
68 and one gemcitabine and radiotherapy.
79
Details and outcomes of these studies are all listed
in the quality and results tables (Tables 5, 6, 9, 11,
15, 16, 19 and 21 (appendix 3)).
Again, from these results, it would appear that
gemcitabine is a reasonable option in second line
treatment, but the small numbers involved and the
Phase II designs fail to provide conclusive evidence
for the use of this drug above and beyond any other
form of chemotherapy in this setting. A high-quality
randomised trial is required before its benefits and
superiority to other regimens can be confirmed.
Quality of life
Gemcitabine as an adjuvant treatment
Neither of the two RCTs
19,20 identified assessed
QoL after the administration of gemcitabine 
in the adjuvant setting. In the authors’ opinion
there is therefore currently insufficient evidence 
to advocate its use as an adjuvant treatment to
improve QoL in patients with resectable 
pancreatic cancer.
Gemcitabine as a single agent therapy
Pancreatic cancer is a devastating disease with a
particularly dismal prognosis, so the maintenance
of QoL is the major goal of palliation. The Burris
RCT
13 provided the best evidence in relation to the
efficacy of gemcitabine in terms of improving this
outcome in advanced pancreatic cancer patients.
Burris and co-workers
13 used CBR to attempt 
to determine the effect of gemcitabine on QoL. 
They demonstrated that it led to significantly more
clinical benefit responders compared with those
randomised to 5-FU (23.8% versus 4.8%, p = 0.0022).
However, the arguments used to criticise the study
design should be reiterated. The 5-FU regimen
might have been administered in a suboptimal
manner, its potential benefits to QoL might not
have been fully expressed and, with such a small
sample size, the results of the study cannot be
regarded as definitive.
It should also be noted that the method used 
to assess QoL (i.e. CBR) is not a validated tool. 
It is based on the assessment of four parameters: 
pain intensity (a daily assessment on a linear
analogue scale), analgesic intake (assessed by
consumption of morphine or its equivalent),
Karnofsky performance status, and weight changeEffectiveness
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(a secondary parameter). In order for patients to
be designated as clinical benefit responders they
must show a significant and sustained 50% improve-
ment in at least one of the three assessed parameters,
with no deterioration in any of the others. If they
remain stable in all parameters they are considered
to be responders if they have not lost 7% of their
body weight, and non-responders if there has been
greater weight loss.
A number of criticisms of this technique have 
been made.
85–87 For example, the primary criteria
for this response is based on patients’ self-reports,
the subjective nature of which could lead to a
‘placebo effect’.
88 Furthermore, the CBR end-
point requires follow-up to be long enough for a
response to be observed. This is an issue for Burris
and colleagues’ study,
13 where the possibility
remains that patients receiving 5-FU were removed
from the study earlier than those on gemcitabine,
so the results are not entirely reliable.
In an effort to overcome this criticism, Hoffman
and Glimelius have attempted to calibrate the 
CBR outcome against the validated QoL tool, the
European Organisation for Research and Treat-
ment of Cancer (EORTC) QoL questionnaire-30.
89
In a total of 151 patients (53 with pancreatic
cancer) they demonstrated that the CBR over-
estimated the beneficial effects in certain patients
and underestimated them in others. They deemed
that the overestimation was due to the fact that 
the CBR did not consider adequately the adverse
effects of chemotherapy, while the underestimation
occurred because the CBR level is dominated by
pain assessment but alterations in other symptoms
will also have a great impact on QoL. Despite these
problems, however, they concluded that the CBR is
a better surrogate marker for clinical benefit in
pancreatic cancer than other methods such as
objective response or performance status.
However, as the ability of the CBR for measuring
the effectiveness of palliative chemotherapy is 
still contentious, the Burris trial has not proved
conclusively the palliative benefit of gemcitabine. 
It therefore becomes necessary to assess other
forms of evidence.
In the study conducted by Storniolo and co-
workers,
33 no formal measurements of QoL in 
the patient population were undertaken by using 
a validated tool. However, a symptom benefit
outcome was assessed by using a scale of disease-
related symptom improvement (DRSI). This is
similar in intent to CBR but is measured retro-
spectively, using data routinely collected by
physicians during the course of a study. These
patients were classified as DRSI responders if they
experienced an improvement in one or more of a
number of parameters without a concomitant fall
in any of the others. The parameters were pain,
analgesic class and Karnofsky performance status
(=20 points). In addition, patients could be classed
as responders if they showed stability in all three of
these parameters but had an increase in weight of
7% or greater. A total of 18.4% of these patients
had experienced DRSI by cycle 4 of the treatment
schedule. However, the reliability of this increase 
is not without question. The value was determined
retrospectively and patients were included in the
assessment only if their records contained suffi-
cient information. A large number of patients
within the trial were therefore omitted from the
DSRI calculation. However, again, the trend was 
for a small benefit attributable to the adminis-
tration of gemcitabine that was consistent with 
the other information available.
Other identified evidence included six 
Phase II studies and one retrospective cohort
study.
27–29,31,32,35,38 QoL is not a valid end-point for
Phase II studies because the aim is to determine
toxicity and anticancer activity. Despite this, a
number of the Phase II trials also used CBR as an
outcome measure and were able to add further
background evidence concerning the efficiency of
gemcitabine. The identified Phase II trials showed
much higher CBR rates than those obtained in Burris
and colleagues’ study, ranging from 27% to 70%.
Although the limitations of the QoL tools used
must be taken into account, it would still appear
that gemcitabine has a slight positive impact on
QoL in advanced pancreatic cancer patients, and is
a reasonable option for improving this outcome in
their palliative care. However, based on the available
evidence, the value of gemcitabine in improving
QoL, over and above other forms of treatment,
remains inconclusive. Burris and co-workers’ trial
showed a significant benefit over 5-FU but, owing
to cautions over the administration of 5-FU, this
cannot be considered to be a definitive result.
Further evidence in the form of the results of high-
quality randomised trials is required to assess fully
the benefit of gemcitabine over other forms of
treatment in terms of patients’ QoL.
Gemcitabine in combination chemotherapy
CBR rates ranging between 45% and 64% 
were reported in seven of the Phase II trials 
examining the combination of gemcitabine and 
5-FU.
43,44,46,48,50,54,56 One study using gemcitabine
and MMC showed a CBR rate of 60%,
67 while theHealth Technology Assessment 2001; Vol. 5: No. 24
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other combination regimens showed rates ranging
between 38% and 78%.
63,69,70,72,75
These results again demonstrate that such chemo-
therapy regimens may offer positive benefit
regarding patients’ QoL, but the available 
evidence cannot be relied upon as definitive.
Further studies, involving more participants 
and of higher methodological quality, are required
before its full impact on QoL can be assessed.
Gemcitabine in chemoradiation
Of the relevant four Phase II studies identified,
76–79
none used any validated QoL instrument. Only
one
77 examined CBR, in which 50% of patients
obtained such a response. This study recruited only
20 patients and is therefore unsuitable to assess the
true impact of gemcitabine chemoradiation on
QoL. Further high-quality randomised trial
evidence is required.
Gemcitabine and hormonal treatment
Only one of the two studies identified
80,81 assessed 
the impact of gemcitabine in combination with
hormonal agents on QoL.
81 It demonstrated a 
47% improvement in the CBR rate when gemcita-
bine and tamoxifen were administered together.
Unfortunately, in this trial only 17 patients were
studied, too few to prove conclusively the benefits
of these agents. Again, further high-quality
randomised trial evidence is required.
Gemcitabine as a second line treatment
Rothenberg and colleagues
29 assessed the 
CBR in patients with metastatic pancreatic 
cancer refractory to 5-FU, demonstrating a 
rate of 27%. Of the other studies that included
relapsed patients, the CBR rates ranged between
44% and 48%. Unfortunately these studies did 
not consist solely of relapsed patients; the 
majority had locally advanced or metastatic 
disease. These results are therefore not fully
representative of the effect of gemcitabine 
as a second line treatment.
Although, based on this limited evidence, it would
appear that second line gemcitabine may offer
some benefit to relapsed patients, there are
insufficient data to determine conclusively its full
value. Further high-quality randomised trial
evidence is required to determine the real value 
of gemcitabine as a second line treatment.
Clinical effect size
Owing to the limited number of studies, and their
small size, poor quality and diversity of design, it is
not appropriate to perform any meta-analyses to
show clinical effect size. The most informative
study was that published by Burris and colleagues,
13
which demonstrated a 16% 1-year survival
advantage to gemcitabine over 5-FU. However, for
the reasons discussed previously, this comparison
has been heavily criticised and the results cannot
be relied upon as definitive.
Adverse effects of intervention
We identified two studies that reviewed the safety
and toxicity of gemcitabine.
90,91 Aapro and co-
workers
90 reviewed data from 979 patients taking
part in 22 completed clinical studies in which they
received gemcitabine 800–1250 mg/m
2 on days 1,
8 and 15 every 28 days. Similarly, Tonato and
colleagues
91 assessed the toxicity profile of this
drug in 790 patients taking part in Phase II trials.
There was some degree of overlap in the results
reported because each group of authors made use
of some of the same Phase II trials. Neither study
was based solely on pancreatic cancer patients;
both consisted of a cohort or individuals with a
range of solid tumours.
Both these studies determined that haematological
toxicity was mild (Table 23). Mucositis and alopecia
were both rare, and nausea and vomiting both
mild. Likewise, both studies demonstrated that
transient rises in serum transaminases, mild
proteinura and haematuria were common but
rarely clinically significant. Renal failure of
uncertain aetiology was reported in seven patients
in the cohort assessed by Aapro and co-workers. 
In this study, 18.9% of patients were seen to
experience transient ‘flu-like symptoms’, with 
mild fever reported in 37.3%. Peripheral oedema
occurred in 20.3% of patients in the absence of
cardiac, hepatic or renal failure.
Tonato and colleagues examined the toxicity
profile according to age. The patient population
was divided into two groups: patients aged less
than 65 years (n = 549) and those older than 65 
(n = 241). Toxicity was not seen to differ significantly
between the two groups, with the exception of
TABLE 23  Toxicities
WHO toxicity         % in Aapro                  % in Tonato
et al., 1998
90 et al., 1995
91
Grade 3     Grade 4     Grade 3     Grade 4
Anaemia 6.8 1.3 6.4 0.9
Leucopenia 8.6 0.7 8.1 0.5
Neutropenia 19.3 6.0 18.7 5.7
Thrombo- 4.1 1.1 6.4 0.9
cytopeniaEffectiveness
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nausea and vomiting, which was lower in the 
older age group.
Both these reviews concluded that gemcitabine is
well tolerated and has a mild toxicity profile.
Ongoing studies
Further high-quality studies are required before
the effectiveness of gemcitabine can be deter-
mined. We identified a total of 11 ongoing RCTs,
23 Phase II studies and three of unclear design, all
of which are listed in appendix 4 (Tables 24–26).
The most important study in relation to adjuvant
treatment is that being conducted by the Euro-
pean Society for the Study of Pancreatic Cancer
(ESPAC). This ESPAC3 trial compares the use of
adjuvant gemcitabine or 5-FU and folinic acid with
surgery alone. Recruitment commenced in 2000;
consequently it will not report for a minimum of 
5 years. However, when complete, it should provide
the necessary information to determine the full
role of gemcitabine in the adjuvant setting.
There is also an ongoing trial in which the 
role of gemcitabine in adjuvant chemoradiation 
is being examined. One arm will involve 5-FU 
and radiotherapy, the other gemcitabine and
radiotherapy. This will further the evaluation 
of the role of adjuvant chemoradiation in this
disease, particularly in the light of the results 
of an earlier trial, ESPAC1.
Cantore and colleagues
18 have published the
preliminary results of a trial comparing
gemcitabine versus 5-FU and folinic acid versus
intra-arterial 5-FU with folinic acid, epirubicin 
and carboplatin. Although the numbers of 
patients involved in this study are low, it should
provide further evidence to allow a fuller
assessment of the effectiveness of gemcitabine 
as a first line treatment. We are not aware of any
other RCTs that compare gemcitabine with either
BSC or 5-FU.
A number of RCTs will examine the use of gemcita-
bine in combination chemotherapy. The remaining
ongoing RCTs identified are all comparing
gemcitabine with experimental treatments.
Conclusion
There is a very poor evidence base by which to
assess the efficacy of gemcitabine. The validity 
of the only RCT that compares this agent with 
the standard treatment of 5-FU has been ques-
tioned and, in combination with the small patient
sample, its results cannot be regarded as definitive.
In addition, owing to the experimental com-
parisons used and the limited results reported, 
it is exceedingly difficult to evaluate or validate 
the other relevant RCTs.
Although from the evidence available it 
would appear that gemcitabine offers similar
survival to 5-FU-based regimens, it is impossible 
to demonstrate conclusively its superiority in 
terms of either survival or QoL. Further evidence 
is required before the full value of gemcitabine 
in pancreatic cancer can be assessed.Health Technology Assessment 2001; Vol. 5: No. 24
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T
his section examines the cost-effectiveness of
gemcitabine in pancreatic cancer. A review of
the existing economic evidence is presented and
an economic evaluation is undertaken.
Existing economic evidence
The search strategy defined in chapter 2 identified
two articles on the economics of gemcitabine as
first line therapy. One published economic evalu-
ation of gemcitabine in pancreatic cancer was
identified
92 and one reference indicated the
existence of a cost-effectiveness analysis by an
Italian group.
93 No published economic evalu-
ations of gemcitabine as second line therapy for
pancreatic cancer were identified.
In addition, an economic evaluation of gemcita-
bine in both first and second line treatment was
included in the Eli Lilly submission to NICE.
Ragnarson-Tennvall and Wilking, 1997
92
An economic evaluation was undertaken of the
treatment of patients diagnosed with pancreatic
cancer in Sweden. This study estimated the incre-
mental cost per life-year gained (LYG) for gemcita-
bine by using a hypothetical analysis of gemcitabine
and BSC versus BSC. The analysis synthesised the
survival rates and resource use (inpatient and
outpatient care) from Burris and colleagues’ 
trial
13 with Swedish epidemiological data.
Using the trial results of an additional survival 
of 38 days (0.104 years), the incremental cost 
per LYG for gemcitabine was estimated to be 
kr. 132,286 (Swedish kroner). Based on current
exchange rates, the cost per LYG was estimated to
be around £14,000. One-way sensitivity analyses
were presented, which indicated that the cost-
effectiveness ratio varies between kr. 64,870 and 
kr. 234,361 (£6900–£24,800). This analysis showed
the cost-effectiveness ratio to be particularly
sensitive, in the upward direction, to any
reductions in incremental survival from treatment
with gemcitabine. The sensitivity analysis also
indicated that costs per LYG are sensitive to
assumptions about patients’ needs for inpatient
and outpatient care, and the required number 
of chemotherapy cycles.
The authors of this Swedish study concluded that
gemcitabine may be a cost-effective treatment
alternative for patients with pancreatic cancer.
However, a number of issues must be noted:
• The analysis was not based on a RCT, but on
data collected retrospectively.
• The study combined Swedish epidemiological
data with US survival results. It may not be
appropriate to combine data from two separate
countries or, on that basis, to generalise with
respect to results from a UK setting.
• The appropriateness of modelling LYGs on such
a modest advantage in survival is questionable.
The cost per LYG is sensitive to small changes in
incremental survival. The sensitivity analysis
demonstrates that that there is much greater
risk at the top end of the range.
• The study does not take account of QoL.
• The authors concluded that further clinical
studies and economic evaluations are required
before any definite conclusions can be drawn
about the cost-effectiveness of gemcitabine.
Trippoli and Messori, 1999
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Using the survival data from Burris and co-workers’
trial
13 and cost data estimated from individual data
on the use of resources and morbidity, preliminary
data were presented, in abstract form, showing the
incremental cost of gemcitabine to be less than
$20,000 compared with 5-FU. Further information
provided details of a preliminary estimate of cost
per quality-adjusted life-year (QALY) analysis using
the quality-adjusted time without symptoms or
toxicity (Q-TWiST) approach (Messori A, Meta-
analysis Study Group of Società Italiana di
Farmacia Ospedaliera [Italian Society of Hospital
Pharmacists]: personal communication, 2000).
This work was not taken beyond the preliminary
estimates owing to issues relating to the quality 
of the cost data.
The Italian evaluation used the Gompertz method
94
to derive area under the curve (AUC) survival estim-
ates for cases and controls. This method, which
requires the extrapolation of survival curves to
infinity, resulted in a discounted (3% annual rate)
estimate of survival gain for gemcitabine patients
over 5-FU of 2.9 months. This estimate compares
with a median (non-discounted) benefit, reported
Chapter 3
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by Burris and co-workers, of 1.24 months (38 days).
An estimate of the incremental LYG is derived by
subtracting the AUC for the 5-FU patients from the
AUC for the gemcitabine patients.
The Q-TWiST method has been used in other
cancer studies
95–98 and involves partitioning
remaining lifetime into periods, with and without
specified symptoms and toxicity, relapse time, and
death. Health state utility values are then assigned
to each of the defined health states (e.g. zero 
for death). Ideally, utility values are derived
empirically by using time trade-off or other
valuation techniques, although they are often
assigned arbitrarily. Multiplying the state utility
values by the duration of time patients spend in
each state and aggregating the results enables 
the calculation of quality-adjusted survival time.
Although the Italian study does not give details 
of the Q-TWiST analysis used, there are earlier
articles from the same research group
95,99 in which
this technique has been applied in an alternative
clinical setting. In this earlier analysis, a utility value
of 1 was assigned to the survival period without
symptoms and toxicity. An arbitrary value of 0.5 
was assigned to toxicity and relapse periods. It is
assumed that a similar approach was used for their
analysis of gemcitabine. Based on the lack of QoL
evidence in pancreatic cancer, it is not possible to
assess the appropriateness of these utility values.
The incremental LYG was estimated to be 
0.22 years. The use of Q-TWiST analysis, as
detailed,
100 produced a quality-adjusted LYG 
of 0.20 years. Based on an incremental cost of
$10,538 (£7500), the Italian analysis results in 
an estimated discounted cost per LYG of $48,000
(£33,500) and a cost per QALY of $52,000
(£36,800). No sensitivity analysis was presented.
The authors argued that this result indicated 
that gemcitabine is cost-effective on the basis 
that $50,000–$80,000 is acceptable for cost per
LYG and cost per QALY estimates.
Eli Lilly industry submission
11
The unpublished industry submission received
from Eli Lilly reviewed the Swedish study but made
no reference to the Italian study. The submission
also included an economic evaluation of first and
second line treatment with gemcitabine for
patients with pancreatic cancer. These evaluations
are reviewed separately below.
Gemcitabine for first line treatment
Their economic evaluation for first line treatment
compared gemcitabine with 5-FU using outcome
and resource-use data made available to them from
Burris and colleagues’ trial.
13 Eli Lilly were involved
as sponsors of that work and have access to data
that were not available to the School of Health 
and Related Research (ScHARR) or to the 
Swedish and Italian teams. A hypothetical
evaluation of gemcitabine compared with BSC 
was also presented.
Cost estimates
Their costing took an NHS perspective, with an 
18-month time horizon. Drug costs and their
administration were assumed to have been incurred
in the first 12 months and were not discounted.
Some costs of follow-up and monitoring beyond 
12 months were discounted as 6%. The standard
dose of 1000 mg/m
2 was assumed for gemcitabine,
and 5-FU was assumed to have been delivered at
the Burris trial rate of 600 mg/m
2 weekly. This
regimen is not generally used in the UK and 
has been shown to be a suboptimal method of
administration in other types of GI cancer.
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It may therefore not be considered as an appro-
priate comparator. However, no other evidence
currently exists.
Patient-specific dosage data were available to Eli
Lilly from the trial data. Oncologists’ visits were
assumed to take place at the time of infusion. 
One GP visit per month was assumed while
patients were receiving chemotherapy. After
disease progression, two GP visits per month were
assumed for symptomatic control and palliation.
Costs for concomitant drugs were included, using
assumptions about drug usage and British National
Formulary prices, but only if the formulations are
used in the UK. Gemcitabine was priced using a
confidential figure reflecting the price to NHS
hospitals. The British National Formulary price of
5-FU was used in their analysis. Hospitalisation data
were available to, and used by, Eli Lilly to estimate
resource use, using a health resource group
casemix analysis and NHS reference costs.
They estimated a cost per patient of £3568 for
gemcitabine and £1261 for 5-FU, a difference of
£2300. The cost of gemcitabine itself accounted for
almost half of the total cost incurred by patients
using the drug. Gemcitabine was shown to be more
expensive than 5-FU for all categories of resource
use, although this may be a result of the longer
survival and, therefore, longer treatment time 
for the patients receiving gemcitabine.
Outcomes
Three end-points were considered, including
progression-free survival, CBR, and the primaryHealth Technology Assessment 2001; Vol. 5: No. 24
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outcome of total survival time. Outcome results
from Burris and co-workers’ trial were used to
derive estimates for these three variables.
Kaplan–Meier survival curves were used to estimate
the AUC and the 95% CI for mean survival. The
discounting of benefits at 6% appears to have been
calculated, although this was not clear from the
table of results. Eli Lilly estimated an overall mean
survival for gemcitabine patients of 6.79 months,
compared with 4.52 months for 5-FU patients, an
incremental benefit of 2.27 months (0.19 life-
years). Based on the shape of the survival curves,
this gave a figure considerably higher than the
median difference of 1.24 months reported by
Burris and colleagues
13 (Table 27). The mean
survival gain for gemcitabine patients, as estimated
by Eli Lilly, was 1.14 months longer than the
median figure reported by Burris (an 83%
increased difference). The incremental differences
for progression-free survival and the CBR were
reported at 1.39 months and 19% respectively.
Cost-effectiveness ratios
Eli Lilly presented a table of average and
incremental cost-effectiveness ratios and rightly
pointed out that it is only the incremental figures
that should be used to inform policy. The central
estimates of incremental cost per LYG and 
cost per CBR are both £12,200, while cost per
progression-free LYG is £19,900. The cost per 
LYG figure is substantially lower than the estimate
presented by Trippoli and Messori.
93 Eli Lilly also
proffered an analysis using a scenario whereby 
5-FU was administered by continuous infusion, 
as is sometimes the case in the UK. They assumed
that the costs for 5-FU would increase by £1900 
(a 50% increase) and that the outcome benefits
would be the same as if drug administration had
been by weekly infusion. Consequently, the
incremental cost per LYG for gemcitabine 
was estimated to fall to £8,900.
A hypothetical analysis was also presented,
comparing gemcitabine with BSC, in which BSC
was assumed to cost nothing and to have the same
benefits as 5-FU in the above analysis. The conser-
vative estimate of the incremental cost per LYG 
was given as £18,900. Synthesising their own
analysis with the results of a recent European trial
comparing gemcitabine with BAY 12-9566, they
produced a second estimate of the incremental
cost per LYG for gemcitabine over BSC of £8650.
Both these figures compare with the Swedish
estimate of £14,000 per LYG.
Sensitivity analysis
The sensitivity analysis prepared by Eli Lilly
indicated that the incremental cost per LYG is
relatively robust, except when survival benefit is
shortened. The 95% CI for survival results in costs
per LYG varying from £10,000 to £25,300. This
cost-effectiveness ratio is clearly more sensitive in
the upward direction. The 95% CI for overall
survival is likely to be overestimated owing to the
influence of covariance. This does not alter the
consequence that any reduction in the gemcitabine
survival gain assumption would result in a propor-
tionately greater increase in the cost-effectiveness
ratio. There is a similar effect for cost per CBR, if
the CBR gain assumption is varied, resulting in
95% CI estimates of £7500–£31,600 per CBR.
Discussion of first line therapy 
economic evaluation 
Eli Lilly have presented a commendable economic
evaluation for gemcitabine as first line therapy.
Their costings are the most comprehensive seen to
date and they have made good use of resource data
made available to them from the pivotal trial. In
terms of outcomes, their use of mean survival has
resulted in a higher survival benefit estimate
compared with that reported in Burris and
colleagues’ trial.
13
A cost-effectiveness analysis was presented, which,
Eli Lilly argue, indicates that first line treatment
using gemcitabine is cost-effective compared with
other NHS funded treatments. This may be the
case, although the comparison of cost per LYG
figures for gemcitabine with cost per QALY figures
for other treatments is not a comparison of like
with like. The assessment of QoL would almost
certainly mean that the cost per QALY would be
higher, possibly markedly higher, than costs per
LYG. Eli Lilly indicated that increased toxicity 
from gemcitabine would reduce QoL, although
they argued that this may be offset by the palliative
effects of this agent. They also argued that some
QoL aspects were reflected in the costs of treat-
ment for adverse drug reactions and in the CBR
measure. The current report has already noted
that CBR is a non-validated and inadequate
indicator of health related QoL. Given the
TABLE 27  Eli Lilly mean survival estimates and medians from
Burris et al., 1997
13
Burris et al., Eli Lilly mean
1997
13 median (months)
(months)
Gemcitabine 5.65 6.79
5-FU 4.41 4.52
Survival gain 1.24 2.27Economic analysis
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importance of QoL considerations in this clinical
setting, in which survival time is short, it is unfortu-
nate that the Eli Lilly report does not add to our
knowledge of the QoL implications of gemcitabine.
As in the Swedish evaluation, the Eli Lilly analysis
showed that the cost-effectiveness parameters are
sensitive to reductions in survival and other
outcome assumptions. The Eli Lilly survival
assumptions were higher than the median figures
reported in the trial and there is some doubt about
the survival gains demonstrated in Burris and co-
workers’ trial (discussed earlier in the current
report). These factors may mean that Eli Lilly’s
central cost per LYG estimate of £12,200 is a
significant underestimate of the actual ratio.
Gemcitabine for second line treatment 
Eli Lilly have presented a tentative economic
evaluation of gemcitabine in second line therapy
for pancreatic cancer, using data from a non-
randomised single-arm study on patients who were
refractory to 5-FU. The lack of a comparator arm
means that only a partial economic evaluation was
possible. The costing analysis employed the same
methodology as for first line treatment and
produced almost identical costs (total cost per
patient £3234). The small reduction, compared
with first line costs, is the result of shorter survival
for the members of this patient group, who have
more advanced disease.
Kaplan–Meier survival curves were again used to
estimate mean survival outcome and CBR was 
once more used as a clinical outcome measure.
Outcome gains were poorer for second line
compared with first line treatment because of the
more advanced nature of the disease. Discounted
LYG was estimated at 5 months (6% discount rate).
This measure is fairly meaningless in the absence
of a comparator treatment, which means that the
incremental survival benefits of gemcitabine
cannot be identified. Eli Lilly argued that CBR is
the more important outcome measure and that the
incremental benefits can be measured by assuming
that CBR is zero for BSC patients. The CBR was
recorded as 27% for gemcitabine.
Eli Lilly reported average costs per LYG and per
CBR of £7800 and £12,000, respectively. These
figures should not be used to inform policy
because they are average and not incremental
costs. They argued that the cost per CBR can be
regarded as incremental if it is assumed that the
CBR benefits of BSC are zero. Their analysis also
assumed that the costs of BSC are zero, so that
their cost per CBR ratio is a conservative estimate,
weighted against gemcitabine. Even if the simpli-
fying assumptions behind their analysis are accepted,
the implicit assumption is that CBR is a valid and
meaningful outcome measure. These assertions
have been questioned elsewhere in this report.
Furthermore, there were no comparator figures
with which to compare their cost per CBR
estimate, although they pointed out that their
estimate is lower than that from their analysis of
first line treatment. Their sensitivity analysis
indicated that costs per CBR are relatively insen-
sitive to changes in input assumptions. Cost per
LYG sensitivity analysis was not undertaken because
of the lack of meaning of the average cost per LYG.
The second line therapy analysis presented by Eli
Lilly is subject to the criticisms of their first line
analysis. Again, QoL was not addressed and their
analysis was not based on the results of a
randomised blinded trial. Gelber
88 has published
his concerns that the lack of randomisation and
blinding in the original study
13 are important
shortcomings. He has also argued that no survival
benefits from gemcitabine in second line treat-
ment have been demonstrated and criticises the
use of the unvalidated CBR measure. 
Summary of Eli Lilly evaluation
Eli Lilly have presented economic evaluations that
indicate that gemcitabine may be cost-effective in
relation to current first line treatments for
pancreatic cancer. They have presented a detailed
and comprehensive costing analysis. It is in the
area of outcome benefits where most uncertainty
exists. The lack of QoL information for patients
with pancreatic cancer is an important drawback in
their analyses, especially given the palliative nature
of the treatment. In addition, their estimates of
survival gains derive from single studies in which
the survival gains from gemcitabine have been
questioned. Their use of Kaplan–Meier and mean
(as opposed to median) survival figures has meant
higher survival gain estimates than would have
accrued by using median figures as presented in
Burris and co-workers’ article. Sensitivity analysis,
for first line therapy in particular, has shown cost-
effectiveness ratios to be particularly sensitive to
reductions in the survival and CBR gain assumptions.
Until better evidence for survival and QoL gains 
is forthcoming (ideally from double-blind RCTs),
the effectiveness and cost-effectiveness of
gemcitabine in this clinical setting remains 
open to question.
Summary of existing economic evidence
In summary, the existing evidence suggests that the
cost-effectiveness of gemcitabine may be in lineHealth Technology Assessment 2001; Vol. 5: No. 24
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with currently available treatments but the quality
of the evidence is poor.
All three analyses
11,92,93 have a number of important
caveats. They are all dependent on the outcome
results from a single (Eli Lilly sponsored) trial. 
The generalisability of the trial’s results are
therefore unproven to date. The Swedish group
acknowledged that their use of Burris and
colleagues’ results may not be appropriate, given
that they used a different treatment comparator
and considering the geographical contexts of the
two studies. Burris and co-workers’ patient group 
is also likely to have included a population with a
different age structure and also a different status to
the Swedish cohort in terms of disease stage and
their experience of operative interventions.
Both the Swedish and the Eli Lilly analyses demon-
strated the upward sensitivity of the cost per LYG
ratio to decreases in incremental survival benefit
from gemcitabine. The effectiveness review
presented in chapter 2 casts some doubt on the
survival benefits demonstrated by Burris and
colleagues’ trial. The questions concerning the
method of administration of the 5-FU may mean
that the survival gains from gemcitabine have been
overestimated. As demonstrated by the sensitivity
analysis, any reductions in survival benefits from
those reported by Burris and colleagues would
reduce significantly the cost-effectiveness of
gemcitabine. Burris and co-workers’ trial, however,
remains the only, and therefore the best, evidence
on survival benefit.
The evidence for the QoL benefit of gemcita-
bine is particularly poor. There is widespread
acknowledgement of the need for a RCT to
confirm the survival benefits of gemcitabine,
particularly to enable the collation of acceptable
QoL data.
87,88,92 Without better information, the
cost-effectiveness of gemcitabine for first and
second line treatment of pancreatic cancer
remains in doubt.
Methods for economic analysis
An economic evaluation has been undertaken to
compare the cost-effectiveness of first line
treatment with gemcitabine with 5-FU. 5-FU has
been used as a comparator because it is widely
used in the UK and available evidence suggests
that it is probably as effective as other drug
regimens.
9 No evidence on which to base an
evaluation of gemcitabine against BSC has 
been identified.
Given that the evidence concerning second line
treatment relies solely on one Phase II trial, no
economic evaluation has been undertaken.
Estimation of net benefits
Survival
In a RCT
13 comparing gemcitabine with the bolus
administration of 5-FU, gemcitabine demonstrated
a significantly improved CBR (23.8% versus 4.8%,
p = 0.0022) and a median survival benefit of 
1.24 months (5.65 versus 4.41, p = 0.0025).
The area under a survival curve indicates the
overall survival time experienced by the cohort.
Therefore, the area between the gemcitabine 
and 5-FU curves indicates the mean difference 
in survival experienced by the two groups. 
The survival gain, taken from the Eli Lilly 
industry submission,
11 estimated in this way 
was 2.27 months (6.79 versus 4.52).
ScHARR did not have access to the raw data
on which this figure was calculated. However, 
our estimate, based on the same methodology, 
but using the published curves from Burris and
colleagues’ article, produced a figure close to the
Eli Lilly value (appendix 5). The Eli Lilly value 
was used in the cost-effectiveness calculations.
Owing to the shape of the survival curves in Burris
and co-workers’ trial, the median survival, although
a useful measure in assessing clinical efficacy,
underestimates the AUC. In the economic analysis,
the mean survival gain used in conjunction with
the mean cost gives a better indication of the cost-
effectiveness ratio.
As noted in the discussion of results in chapter 2,
the survival benefits demonstrated by the RCT
have been questioned. The 1-year survival rate in
the 5-FU arm was unusually low, at 2%. The
median survival for the 5-FU arm may also be
considered to be low at 4.41 months (mean 4.52).
In trials by Glimelius and colleagues
12 and by
Palmer and co-workers
83 that compared combined
5-FU and other chemotherapy agents with BSC, the
median survivals for 5-FU were 6.0 and 7.6 months
respectively. In these trials, the median survival for
BSC was 2.5 and 3.5 months respectively (mean 
4.2 and 4.9).
12,83 These mean survivals for BSC 
are comparable with the 5-FU mean survival in
Burris and colleagues’ trial (Figure 2).
Effectiveness of different 5-FU regimens
The weekly bolus 5-FU regimen, as used in the
Burris trial, is not generally used in the UK. How-
ever, a number of different 5-FU regimens areEconomic analysis
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used. The De Gramont regimen consists of 5-FU
400 mg/m
2 by bolus intravenous injection plus 
400 mg/m
2 22-hour infusion plus high-dose folinic
acid 200 mg/m
2 2-hour infusion for 2 days at 
14-day intervals. A modified De Gramont regimen
(5-FU/folinic acid), which allows the drug to be
administered on an outpatient basis, is also used.
The protracted venous infusion (PVI) regimen
consists of 5-FU 300 mg/m
2 per day administered
continually via an ambulatory pump. The Mayo
regimen consists of 5-FU 425 mg/m
2 plus low-dose
folinic acid 20 mg/m
2 by bolus injection, adminis-
tered every 5 days and repeated at 28-day intervals.
There is strong evidence to show that, in other
treatments of GI cancer, the use of bolus 5-FU
alone would be considered inferior in terms of
response rates and efficacy. Given the absence of
evidence on the effectiveness of alternative 5-FU
regimens, the mean survival gain of gemcitabine
over 5-FU is assumed to be the same for the different
regimens. However, this may well mean that the
survival gains for gemcitabine are overstated.
Quality of life
No QoL evidence has been identified that
compares gemcitabine with 5-FU or with BSC by
using validated QoL instruments. As discussed in
the previous chapter, the use of CBR as presented
in Burris and colleagues’ trial has not been
validated and caution should be exercised in the
interpretation of this outcome measure.
However, given the significance of QoL for patients
with pancreatic cancer, an illustration has been
provided, using Q-TWiST analysis, of the potential
impact of QoL adjustments on survival (appendix 6).
Estimation of net costs
No published UK costs for the use of gemcitabine
in pancreatic cancer were identified. A value for
the drug cost, based on a standard 1000 mg/m
2
dose for an assumed average patient of 1.8 m
2, 
has been obtained from the Leeds Cancer Centre
(Crellin A, Yorkshire Centre for Clinical Oncology,
Cookridge Hospital, Leeds: personal communication,
2000). It is assumed that gemcitabine is given by a
30-minute intravenous infusion, once weekly for 
7 weeks out of 8, and then, for subsequent cycles,
once weekly for 3 weeks out of every 4. It is also
assumed that infusions are given on an outpatient
basis. The cost of an outpatient visit is based on 
the national average cost of a medical oncology
outpatient appointment of £109.
101 The costs for
hospitalisations and concomitant medicines have
been taken from Eli Lilly’s data.
The cost of 5-FU is dependent on the type of
delivery. Two regimens, both commonly used in
the UK, are considered: the De Gramont regimen,
which is the more expensive, having high inpatient
and chemotherapy costs; and the PVI 5-FU regi-
men, which allows the drug to be administered 
in the home setting. Although, for the PVI 5-FU
regimen, there are additional costs associated with
the pump and the insertion of a central line, it
offers the advantage of low numbers of inpatient
and outpatient visits. The costs for the modified 
De Gramont regimen are similar to those for the
PVI regimen; these are not considered separately.
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The mean treatment costs per month for PVI 5-FU
and for the De Gramont regimen are taken from
Ross and colleagues’ publication.
102 Updated costs
for chemotherapy and consumables have been
obtained from the Royal Marsden Hospital
(Cunningham D, Royal Marsden Hospital, Surrey:
personal communication, 2000). Other costs,
including concomitant medications and intra-
venous fluids, inpatient stays, outpatient visits,
operations and the provision of a telephone
helpline service, have been taken from Ross and
co-workers’ data
102 and inflated to year 2000 prices.
Owing to the absence of data on nursing time to
set up infusions and pharmacy costs, these were
excluded from the article. In addition, general
practitioner visits and travel expenses were not
taken into account. Costs relating to investigations
and tests have been omitted from our analysis
because it was assumed that patients receiving
gemcitabine or 5-FU would receive similar
investigational procedures.
Monthly and total treatment costs, as estimated by
ScHARR, are given in Tables 28 and 29. The total
treatment costs were calculated by multiplying the
cost per month by the treatment period.
It has been assumed that patients are treated until
disease progression. Time to progression data were
taken from the Eli Lilly submission.
11 ScHARR
estimates of these figures, based on the published
curves from Burris and colleagues’ trial, produced
values close to the Eli Lilly value.
NHS savings from use of gemcitabine
It is not possible to conclude from published data
whether savings would accrue from the use of
gemcitabine. Prolonged survival simply delays the
costs of the eventual decline of a patient.
Estimation of cost-effectiveness
Estimation of cost per life-year gained
The mean survival gain for gemcitabine (2.27 months)
was combined with the incremental cost of the
gemcitabine over 5-FU to calculate a cost for
gemcitabine per LYG (Figure 3).
Based on comparison with the PVI 5-FU regimen,
the incremental cost of gemcitabine was estimated
to be £16,543 per LYG. On using the De Gramont
regimen, the corresponding figure is £7209.
Sensitivity analysis on cost per life-year gained
Costs
Cost of gemcitabine. The cost per month of
gemcitabine from the Eli Lilly submission was
lower than the cost estimate used in our analysis
(Table 29). It was derived by dividing the cost 
per patient by the time to progression (3.93
months). The Eli Lilly figure included an estimate
of visits to health professionals based on the
unpublished evidence from Burris and colleagues’
trial. We have excluded this cost because no
estimate for it was identified for inclusion in our
estimate of 5-FU costs. The Eli Lilly estimates for
the cost of the drug and the infusion are lower 
and are based on individual dosage data from the
Burris trial.
The ScHARR drug cost estimates were based on a
standard 1000 mg/m
2 dose for an assumed average
patient of body surface area 1.8 m
2, assuming that
all patients are treated until disease progression.
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FIGURE 3 Estimate of incremental cost per LYG of gemcitabine
versus 5-FU
TABLE 28  Dose and cost of different drug regimens
Regimen Drugs in regimen Dosage (mg/m
2) Length of treatment Total treatment drug cost
(months) (£)
Gemcitabine Gemcitabine 1000 (30-min infusion) 3.93 4839
De Gramont 5-FU 400 (bolus injection) 1.78 3478
5-FU 400 (22-h infusion)
Folinic acid 200 (2-h infusion)
5-FU PVI 5-FU 300 (continuously every day) 1.78 1715
TABLE 29  Monthly treatment costs for gemcitabine
ScHARR (£)        Eli Lilly (£)
Total cost 1419.79 1219.59
Total cost excluding  1419.79 1157.75
health professionalsEconomic analysis
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Substituting the Eli Lilly cost estimate for gemcita-
bine in the analysis reduces the incremental cost
per LYG for gemcitabine against PVI 5-FU to 
£9468. The cost of visits to health professionals 
is not included in the 5-FU cost, so, if this is
omitted from the calculation, the cost per LYG 
falls to £8527.
Cost of protracted venous infusion 5-fluorouracil.
The cost per month of PVI 5-FU outlined in the Eli
Lilly submission was higher than the cost estimate
used in our analysis. A comparison of the costs is
given in Table 30.
The key differences are that the Eli Lilly estimates
were higher for infusions (pump and flushings)
and operations, and lower for hospitalisations. 
The cost of checking and flushing of a central
line/infusion pump will depend on the frequency
of visits to the hospital. The Eli Lilly estimate
assumed that this would involve a weekly visit. 
More typically, this occurs less frequently, once
every 2 or 3 weeks for stable patients (Crellin A,
Yorkshire Centre for Clinical Oncology, Cookridge
Hospital, Leeds: personal communication, 2000).
In one cancer centre where a helpline is available
to support patients at home, it has been shown that
visits to the hospital can be reduced to once every
6 weeks (Cunningham D, Royal Marsden Hospital,
Surrey: personal communication, 2000). The Eli
Lilly estimate assumed that central line insertion
and removal would be undertaken during an
inpatient stay; however, for many providers, 
this is undertaken as a day case procedure.
Substituting the Eli Lilly estimate of the cost of 
PVI 5-FU in the analysis changes the incremental
cost per LYG for gemcitabine to £15,565. If the
central line insertion and removal are assumed 
to be day case procedures, and the frequency of
checking and flushing of the central line and
pump is once every 6 weeks, not weekly, the cost
per LYG is £20,361.
Treatment period. Despite changes in the
assumptions concerning the costs of PVI 5-FU and
gemcitabine in the above sensitivity analysis, the
cost-effectiveness of gemcitabine remains within
the levels of treatments currently used in the NHS.
Discrepancies in costs of both PVI 5-FU and gem-
citabine remain. A difference of £4720 between
the total treatment costs of the two drugs would
correspond to a cost per LYG greater than £25,000.
Survival
The survival gain for gemcitabine against 5-FU in
Burris and co-workers’ trial has been questioned. The
following sensitivity analysis shows the impact on the
cost per LYG if the survival difference is decreased.
The median survival reported in Burris and
colleagues’ trial is supported by the results of a
number of further trials, including Moore and 
co-workers, who noted a median survival of 
6.4 months.
22 However, there is some evidence to
suggest that survival with gemcitabine may be lower
than this. Storniolo and colleagues reported a 5.1-
month median survival in a study of 2380 chemo-
naive patients,
33 and Colucci and co-authors
reported a 4.85-month median survival.
63 On
reducing the mean survival gain for gemcitabine 
by the same proportion as the median survival 
(as in the Storniolo report), the cost per LYG
increases further from £16,543 to £20,087. This
assumes that the treatment period, based on the
time to progression, is also reduced proportionally.
The cost per LYG results presented in Figure 3 are
based on the assumption that the PVI 5-FU survival
will be the same as that for 5-FU from Burris and
colleagues’ trial. As noted in the discussion of results
in chapter 2, this may understate the 5-FU survival
benefit. There is no evidence to allow accurate
identification of the survival benefits of PVI 5-FU
against gemcitabine. In addition, anecdotal
evidence to date suggests that the addition of
folinic acid to the PVI 5-FU regimen of patients
with pancreatic cancer may enhance the survival
benefits with little additional cost (Crellin A,
Yorkshire Centre for Clinical Oncology, Cookridge
Hospital, Leeds: personal communication, 2000).
Within the Eli Lilly submission, the 95% CI for
mean survival gain was presented. Based on this,
the company presented a sensitivity analysis for the
upper and lower 95% CIs. The base case cost per
LYG was £12,206 and the upper and lower CI costs
were £10,062 and £25,316 respectively. Given our
higher estimate of the base case, this would
increase the cost per LYG based on the lower 
CI to levels above £25,000.
TABLE 30  Monthly treatment costs for PVI 5-FU
ScHARR (£) Eli Lilly (£)
(£/month) (£/month)
Drug cost 123.00 130.46
Drug administration
Infusion (incl. pump and flushings) 166.68 429.11
Hospitalisations 505.08 139.00
Visits to health professionals                N/A 71.51
Concomitant medications 18.53 23.74
Operations 148.29 271.28
Total 961.58 1065.10
N/A, not availableHealth Technology Assessment 2001; Vol. 5: No. 24
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Estimation of cost per quality-adjusted 
life-year gained
Given the significance of QoL for patients with
pancreatic cancer, an illustration shows, by using
Q-TWiST analysis, the potential impact of QoL
adjustments on survival (appendix 6).
The Q-TWiST method compares treatments on the
basis of quality-adjusted survival times. The overall
survival of patients is divided into different health
states, which, in turn, are weighted according to the
QoL in each health state to derive a QALY estimate.
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The three health states identified in Burris and co-
workers’ trial were: time in clinical benefit; time
before progressive disease when not in clinical benefit;
and time from disease progression to death. We fol-
lowed the illustration used by Messori and colleagues
in their articles on ovarian cancer,
95,99 assigning
estimated utilities of 1.0, 0.5 and 0.5 to each of the
health states respectively. Sensitivity analysis was
undertaken on the utility variables to encompass a
wide range of values of QoL because, clearly, these
utilities are illustrative and have no empirical basis.
Based on Burris and co-workers’ survival data, 
the mean LYG between patients treated with
gemcitabine and those treated with 5-FU is 0.19
years. When using the costs of the PVI regimen,
the cost per QALY is £16,543. On utilising the Q-
TWiST methodology, with estimated values for the
QoL utilities as given above, the QALYs gained are
estimated at 0.148. This implies an incremental
cost per QALY gained of £21,088.
Sensitivity analysis on cost per quality-adjusted
life-year
QoL in different health states is unknown.
Sensitivity analysis was used to explore the impact
of changes in the utility scores on the cost per
QALY (see appendix 6 for further details).
In the base case, time in clinical benefit, time
before progressive disease when not in clinical
benefit, and time from disease progression to
death (relapse period) were assigned utilities of
1.0, 0.5 and 0.5 respectively. However, assuming
that patients who are experiencing clinical benefit
have perfect health (a utility score of 1) when they
are receiving chemotherapy is unlikely. In addition,
the time to disease progression and time from
disease progression to death may have a higher or
lower QoL than the assumption of 0.5.
A range of sensitivities were explored in terms of
changes in the utility value of each health state
independently and changes in the utility value of
more than one health state at a time. In many
cases this resulted in only small changes in the cost
per QALY relative to the base case. The cost per
QALY gained was relatively sensitive to assumptions
about QoL in the relapse period, rising by 30% to
£26,115 when the QoL in the period was reduced
from 0.5 to 0.1.
The base case scenario assumes that the two drugs
have the same utility in each health state. It seems
reasonable, although not certain, that QoL would
be similar for both drugs when patients are experi-
encing clinical benefit and during the period of
disease progression until death. It is in the health
state of time to progression when not in clinical
benefit that there is most likelihood of differences
in utility values. Trial data
13 showed that, although
both drugs were well tolerated, patients treated
with gemcitabine experienced more frequent and
more severe toxicities than those treated with 5-FU,
so it may be reasonable to expect that those
treated with gemcitabine would have a lower QoL
than if they were receiving chemotherapy. The cost
per QALY was sensitive to changes in the utility of
this health state. When the utilities for 5-FU were
increased, or those for gemcitabine were decreased
by 0.2, then the QALY gain reduced from 0.148 to
0.103, giving a cost per QALY of £30,460.
The utilities used in the sensitivity analysis are
illustrative only and have no empirical basis.
Further evidence on QoL is needed.
Conclusions
Preliminary estimates of the cost per LYG for
gemcitabine as first line therapy suggest that it may
be around £16,543. However, the clinical evidence
on which the analysis is based is poor. Uncertainty
relating to the evidence of effectiveness means that
the cost-effectiveness analysis cannot be considered
to be robust.
No published UK estimates of the cost of
gemcitabine have been identified. The cost of 
5-FU administration varies by regimen and also by
provider for the same regimen. The cost difference
between gemcitabine and 5-FU is therefore not
known with certainty. The sensitivity analysis
undertaken does however demonstrate that the
cost per LYG remains within acceptable limits,
despite changes to the cost assumptions.
The results of the analysis on cost per QALY
gained are purely illustrative because no QoL 
data have been identified. However, the analysis
demonstrates that the addition of a QoL adjust-
ment is likely to result in a cost per QALY gained
that is higher than the cost per LYG.Economic analysis
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Impact on the NHS budget
The impact on the NHS budget would depend on:
• the number of patients with pancreatic cancer
receiving chemotherapy
•t he change in the market share of gemcitabine
if a positive NICE recommendation is made.
The incidence of pancreatic cancer is not changing
dramatically. For men, it has been declining at
3–4% every 5 years since the mid-1970s, while the
incidence for women increased slightly until the
end of the 1980s and has subsequently plateaued.
The number of patients diagnosed with this cancer
is therefore not expected to change dramatically.
The introduction of guidance on the diagnosis
and treatment of upper GI cancers
9 is anticipated
to increase the number of patients who will be
referred to specialist oncologists. This will raise 
the number who are considered for chemotherapy.
Within the next few years the proportion of
patients receiving chemotherapy may rise to
around 35%. This is based on the assumption 
that 10–15% of patients may undergo resection 
in the future. Of the remaining 85–90% it is
assumed that only 40% will be suitable for
palliative chemotherapy.
If there is a positive NICE recommendation, the
market share of gemcitabine is likely to increase. 
It is unlikely that this drug would achieve a 100%
market share, and any changes are likely to be
gradual, occurring over a number of years. In the
company submission, Eli Lilly assumed a market
share of gemcitabine of 55% by 2002. They
provided no indication of their expectation of
market share beyond that date.
Eli Lilly suggested that the impact on the NHS
budget would be likely to be in the order of
£330,000–£640,000 per annum. They gave an
upper ceiling of £2 million per annum by 2002,
based on the assumption that all patients with
locally advanced or metastatic disease (estimated 
to be 71% of all patients) receive chemotherapy.
The Eli Lilly estimates take account only of the
drug costs and the medications used to treat side-
effects. This is not unreasonable, given that this is
the only resource that will directly impact on the
NHS budget. However, it should be noted that
other resource use will also change, including 
costs relating to chemotherapy infusions, hospital-
isation and visits to and by health professionals
(e.g. Macmillan nurses). In particular, the use 
of gemcitabine requires an outpatient visit 
(or in some instances a day case visit) once a 
week for 7 weeks out of 8 and then for 3 weeks 
out of every 4. Continuous infusion regimens
require fewer hospital visits, which may allow 
a greater throughput of patients within 
existing facilities.
The cost estimates provided by Eli Lilly are
considered to be reasonable, although the
suggestion that the use of gemcitabine may go
some way to addressing regional inequality in
survival
11 should be viewed with caution.Health Technology Assessment 2001; Vol. 5: No. 24
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Geographical variability in 
availability of gemcitabine
The availability of gemcitabine currently varies
according to geographical location within the UK.
Some centres and units have funding for gemcita-
bine, while this has been refused at some hospitals,
including a number of specialist centres.
11
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Gemcitabine for first line 
treatment of pancreatic cancer
Quality of the evidence
Evidence for the effectiveness of gemcitabine for
the first line treatment of pancreatic cancer is
limited. One RCT exists, published by Burris and
colleagues in 1997,
13 which compares the effect 
of gemcitabine with that of 5-FU in patients with
pathologically confirmed, locally advanced or
metastatic pancreatic cancer. This study does show
a statistically significant survival benefit for the use
of gemcitabine compared with 5-FU, although
there are questions that cast doubt on the validity
of its results. The median survival gain from Burris
and co-workers’ trial was 1.24 months (mean 2.27).
This is a relatively small gain, although it should be
noted that, for patients with a short remaining
lifetime, particularly those who are younger, 
this period of time is often considered to be
extremely valuable.
The limitations of the trial have been outlined in
chapter 2. Burris and colleagues’ trial
13 includes
only 126 participants; results based on such a small
sample cannot be regarded as definitive. In the
control arm, the 5-FU was administered as a bolus
infusion. There is little direct evidence to suggest
that different 5-FU schedules are any better or
worse than each other in pancreatic cancer. How-
ever, there is very strong evidence to show that, in
other areas of GI cancer therapy, bolus 5-FU alone
would be considered to be inferior in terms of
response rates and efficacy. It is difficult to imagine
bolus 5-FU alone being used in current practice in
the UK, either within trials or as standard practice;
it therefore cannot be considered to be a suitable
comparator. Indeed, the results of Glimelius and
co-workers,
12 in terms of survival and equivalent
toxicity, would support the suboptimal nature of
the 5-FU in Burris and colleagues’ trial.
No evidence on QoL was identified. The use of
CBR as a proxy measure for QoL in Burris and co-
workers’ trial suggests that gemcitabine may offer
benefit, but CBR has not been validated and its
clinical relevance must be interpreted with caution.
Gemcitabine was reviewed and approved by the US
Food and Drug Administration (FDA) Oncologic
Drugs Advisory Committee in 1995. However, 
in 1996, Gelber, a member of this Committee,
highlighted ongoing concern over the ability of
CBR to capture adequately patients’ assessment 
of QoL, and stated that, “it is not clear whether 
the current criteria for Clinical Benefit Response 
is indeed acceptable to the FDA”.
88 Despite this,
however, gemcitabine is the standard treatment 
for pancreatic cancer in the USA, and indeed in
many European counties.
Quality of life issue
QoL is an important issue. Pancreatic cancer is a
serious disease with a profound impact on QoL.
Severe pain is a common symptom. It also causes
jaundice, weight loss, poor appetite, vomiting,
general GI problems and diabetes.
9 The role of
chemotherapy in pancreatic cancer and its impact
on QoL is not clear cut. Benefits in terms of
survival time and the alleviation of symptoms 
may be outweighed by the cost of toxicity and
deterioration in QoL.
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There is some evidence to support the role of
chemotherapy in advanced pancreatic cancer. 
In 1996, Glimelius and colleagues reported on 
90 patients with advanced pancreatic and biliary
cancer who were randomised to receive chemo-
therapy (5-FU, leucovorin with or without
etoposide) plus BSC or BSC alone.
12 Overall
survival was significantly longer in the chemo-
therapy group (median 6 versus 2.5 months, 
p < 0.01). In addition, the patients in the chemo-
therapy group had better emotional functioning
together with improved performance in role
functioning, better appetite and less pain. 
Overall QoL-adjusted survival was 4 months 
in the chemotherapy group and 1 month in 
the BSC group. These authors concluded that
chemotherapy can add to both quantity and 
quality of life in advanced pancreatic cancer.
Toxicity
Gemcitabine as a first line therapy has been shown
to be well tolerated and to have a mild toxicity
profile. In Burris and co-workers’ trial it was shown
to have a more frequent and more severe toxicity
profile than 5-FU. This, once again, may point to
the possibility that a suboptimal dose of 5-FU was
delivered because the toxicity of bolus 5-FU would
Chapter 5
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generally be expected to be similar to that relating
to gemcitabine.
Treatment costs
The drug cost of gemcitabine is more expensive than
5-FU, but overall costs are partly offset by simplicity
of drug administration. No inpatient admission is
required, as in the case of the De Gramont
regimen. Costs relating to pump and central line
insertion and removal, as required for PVI 5-FU,
are avoided, as are the potential complications
arising from the use of central venous catheters. 
In addition, some cancer centres and/or units may
not have the infrastructure necessary to support
PVI 5-FU schedules. One major advantage of
continuous infusion regimens is the potential to
reduce the number of hospital visits per patient,
which is beneficial to both patients and providers.
Preliminary estimates of the cost per LYG 
suggest that gemcitabine should not be dismissed, 
because it is a potentially cost-effective treatment
for pancreatic cancer. However, these results are
sensitive to survival assumptions; small changes in
survival produce cost per LYG values well above the
level achieved by currently available treatments. 
It should be noted that the introduction of a QoL
adjustment to survival is likely to diminish gem-
citabine’s survival advantage, resulting in a cost 
per QALY that is higher than the cost per LYG.
Gemcitabine for second line
treatment of pancreatic cancer
Only one Phase II trial (by Rothenberg and
colleagues
29) has used gemcitabine solely as a
second line treatment. Although this demonstrated
a median survival of 4 months and a 1-year survival
of 4%, no additional evidence is available to support
this trial. Phase II trials alone should not form the
basis of the establishment of standard therapy.
Other applications of gemcitabine
A trial conducted by the European Society for the
Study of Pancreatic Cancer (ESPAC3) began
recruiting in 2000. This study will compare the use
of adjuvant gemcitabine or 5-FU and folinic acid
with surgery alone.
The use of gemcitabine as part of a combination
chemotherapy regimen appears to offer a 
possible way forward. Evidence to date 
comprises only Phase II studies. These have 
been presented as abstracts, the results are
inconsistently reported, and the numbers of
participants entering the studies are very small. 
It would appear from the limited details 
available that the administration of such 
regimens is reasonable. Further studies and
randomised trials should be conducted 
before the value of gemcitabine in combination
chemotherapy is assessed.
Need for further research
The prognosis for pancreatic cancer patients
remains poor. For those with an unsatisfactory
performance status the emphasis should 
remain on symptom control and involvement 
of a palliative care team. For patients with a 
good performance status, chemotherapy may 
offer benefit. However, no chemotherapy drugs
have yet demonstrated response rates higher 
than 20%. Gemcitabine offers, at best, a small
increase in survival over 5-FU. Further RCTs 
are required.
Until Phase II studies with existing or new drugs,
alone or in combination, demonstrate significantly
improved activity in pancreatic cancer, randomised
studies are likely to be directed towards looking at
toxicity, QoL, and any small survival benefits that
may be obtained with gemcitabine alone compared
with a modern 5-FU-based protocol or a combination
of the two.
Evidence for QoL benefits of gemcitabine is
particularly poor. There is almost universal
acknowledgement of the need for a double-blind
RCT to confirm the survival benefits of this agent,
particularly to enable the collation of acceptable
QoL data.
87,88,92Health Technology Assessment 2001; Vol. 5: No. 24
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G
emcitabine has not been shown conclusively 
to be superior to 5-FU in terms of survival 
or QoL. There is, however, no evidence to suggest
that gemcitabine is worse that 5-FU. Preliminary
estimates of the cost per LYG for gemcitabine as
first line therapy suggest that this agent should 
not be dismissed, but these results are not robust.
Further evidence on survival, QoL and cost is
required before any definite conclusions can be
drawn about cost-effectiveness. Additional research
is required in the form of a RCT to confirm the
survival benefits of gemcitabine compared with a
modern 5-FU-based protocol and to provide good
QoL data.
The evidence for the use of gemcitabine as second
line therapy is inconclusive. Further confirmation
from high-quality randomised trials is required. 
In addition, further evidence in the form of the
results of RCTs is also required concerning the 
use of gemcitabine as adjuvant treatment and in
combination therapy.
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MEDLINE (OVID BIOMED 1966–)
1 gemcitabine.af.
2 103882 84 4.rn.
3d ifluorodeoxycytidine.tw.
4d ifluorocytidine.tw.
5 gemzar.tw.
6 ly 188011.tw.
7 ly188011.tw.
8 dfdc$.tw.
9 or/1–8
10 Pancreatic neoplasms/
11 exp Pancreas/
12 Pancreatic diseases/
13 11 or 12
14 Neoplasms/
15 Digestive system neoplasms/
16 Carcinoma/
17 Adenocarcinoma/
18 or/14–17
19 13 and 18
20 (pancrea$ adj5 (cancer$ or neoplasm$ or
neoplasia$ or carcinoma$ or tumor$ or
tumour$ or adenocarcinoma$)).tw.
21 10 or 19 or 20
22 9 and 21
EMBASE (OVID BIOMED 1980–)
1 exp Pancreas tumor/
2( neoplas$ or tumor$ or malignan$ or cancer
or carcinoma or adenocarcinoma).hw.
3 Pancreas disease/
4 exp pancreas/
53  o r  4
62   and 5
7 (pancrea$ adj5 (cancer$ or neoplasm$ 
or neoplasia$ or carcinoma$ or 
tumor$ or tumour$ or 
adenocarcinoma$)).tw.
81   or 6 or 7
9 gemcitabine.af.
10 gemzar.af.
11 103882 84 4.rn.
12 ly 188011.af.
13 ly188011.af.
14 dfdc$.af.
15 difluorocytidine.af.
16 difluorodeoxycytidine.af.
17 or/9–16
18 8 and 17
Science Citation Index (Web of
Science 1981–)
Topic = ((gemcitabine or gemzar or difluoro-
deoxycytidine or difluorocytidine or ly 188011 or
ly188011 or dfdc*) and pancrea*); DocType=All
document types; Language=All languages;
Databases= SCI-EXPANDED, SSCI, A&HCI;
Timespan=All Years;
Cochrane Library (CDSR and
CENTRAL/CCTR) (2000 Issue 3)
#1 GEMCITABINE
#2 GEMZAR
#3 DIFLUORODEOXYCYTIDINE
#4 DIFLUOROCYTIDINE
#5 DFDC*
#6 ((((#1 or #2) or #3) or #4) or #5)
#7 PANCREA*
#8 #6 and #7
NHS CRD DARE, NHS EED and
HTA (complete databases)
gemcitabine or difluorodeoxycytidine or difluoro-
cytidine or gemzar or dfdc$ or 103882(w)84 or
ly188011 or ly(w)188011/All fields AND
pancrea$/All fields
PubMed (last 180 days from 
31 August 2000)
#11 Search #9 and #10 Limits: 180 days
#10 Search pancrea* Limits: 180 days
#9 Search #1 or #2 or #3 or #4 or #5 or #6 or #7
or #8 Limits: 180 days
#8 Search dfdc* Limits: 180 days
#7 Search ly188011 Limits: 180 days
#6 Search ly 188011 Limits: 180 days
#5 Search gemzar Limits: 180 days
#4 Search difluorocytidine Limits: 180 days
#3 Search difluorodeoxycytidine Limits: 180 days
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#2 Search 103883 84 4 Limits: 180 days
#1 Search gemcitabine Limits: 180 days
OHE HEED (complete database)
Search terms
gemcitabine
difluorodeoxycytidine
difluorocytidine
gemzar
dfdc*
103882 84 4
ly188011
ly(w)188011
Fields searched
Abstract
All data
Article title
Book title
Drug names
Keywords
Technology assessed
Other sources consulted
AÉTMIS (Agence d’Évaluation des Technologies et
des Modes d’Intervention en Santé)
AHFMR (Alberta Heritage Foundation for 
Medical Research)
AHRQ (Agency for Healthcare Research 
and Quality)
Alberta Clinical Guidelines Programme
ARIF (Aggressive Research Intelligence Facility)
CancerGuide: finding clinical trials on the Internet
CancerWEB
CCOHTA (Canadian Co-ordinating Office for
Health Technology Assessment)
CCT (Current Controlled Trials)
CenterWatch trials register
Centre for Clinical Effectiveness, Monash University
Centre for Health Economics, York University
CPG Infobase (Canadian Medical Association,
Clinical Guidelines Programme)
Current Research in Britain
DTB (Drug and Therapeutics Bulletin)
eGuidelines
EMEA (European Agency for the Evaluation of
Medicinal Products)
FDA (Food and Drug Administration)
Harvard CUA (Cost–utility analysis) database
HERC (Health Economics Research Centre),
Oxford University
HERG (Health Economics Research Group),
Brunel University
HERU (Health Economics Research Unit),
Aberdeen University
HSRU (Health Services Research Unit), 
Aberdeen University
HSRU (Health Services Research Unit), 
Oxford University
HSTAT (Health Services/Technology Assessment
Text, US National Library of Medicine)
IHE (Institute of Health Economics), Alberta
INAHTA (International Network of Agencies for
Health Technology Assessment) Clearing House
Manitoba Guidelines and Statements
MRC (Medical Research Council) Funded 
Projects Database
MSAC (Medical Services Advisory 
Committee), Australia
MTRAC (Midland Therapeutic Review and
Advisory Committee)
National Guideline Clearinghouse
NCCHTA (National Co-ordinating Centre for
Health Technology Assessment)
NCI (National Cancer Institute)
NHMRC (National Health and Medical Research
Council), Australia
NHS Centre for Reviews and Dissemination, 
York University
NHS R&D Programmes
NIH (National Institutes of Health) Consensus
Development Programme
NIH Clinical Trials database 
(ClinicalTrials.gov)
North of England Guidelines, University 
of Newcastle
NRR (National Research Register)
SBU (Swedish Council for Health 
Technology Assessment)
SHPIC (Scottish Health Purchasing 
Intelligence Consortium)
SIGN (Scottish Intercollegiate 
Guidelines Network)
Therapeutics Initiative (Vancouver)
TRIP (Turning Research into Practice) database
Wales, Health Evidence Bulletins
Wessex DEC (Development and Evaluation
Committee) reports
West Midlands DES (Development and Evaluation
Service) reportsHealth Technology Assessment 2001; Vol. 5: No. 24
39
Section 1: Study information
Unique study identifier:
First authors:
Title:
Publication date:
Year of data:
Final publication: Y/N
Funding source:
Government        Pharmaceutical        Private        Unfunded        Unclear
Outcome Yes Yes but Not Definition/ Value
(time no time given indication
stated) stated as stated in
article
Median survival (months)
Survival at time point
Surgery
Clinical benefit response
Median progression-free 
survival (months)
Time to treatment failure 
(months)
Partial response rate
Symptomatic response rate
Objective response rate
Overall response rate
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Section 2: study design and conduct
Randomisation before treatment?
YesN oUnclear
Please indicate the degree of concealment according to the following criteria:
A: adequate
B: possibly adequate
C: clearly inadequate
D: not randomised
Description Degree of concealment
Details of method of randomisation
Inclusion criteria for participants
Exclusion criteria for participants
If RCT, complete Jadad scoring system.
Jadad scoring
Give a score of 1 point for each “yes” or 0 points for “no”.
1. Was the study described as randomised (this includes the use of words such as 
randomly, random and randomisation)?
2. Was the study described as double blind?
3. Was there a description of withdrawals and drop-outs?
Give 1 additional point if the method to generate the sequence of randomisation was described and if it
was appropriate (table of random numbers, computer generated etc.).
Deduct 1 point if this method was inappropriate (patients allocated alternately, according to date of birth,
hospital number etc.).
Give 1 point if the method of double blinding was described and was appropriate (identical placebo,
active placebo, dummy etc.).
Deduct 1 point if the study was described as double blind but the method of blinding was inappropriate
(e.g. comparison of tablet versus injection with no double dummy).Health Technology Assessment 2001; Vol. 5: No. 24
41
Participants who were included in the study but did not complete the observation period or who were not
included in the analysis must be described. The number and reasons for each withdrawal must be stated.
If there were no withdrawals it should also be stated in the article. If there is no statement on withdrawals,
this item must be given no points.
Overall Jadad score:
Section 3: study details
Single site Multicentre
Duration of follow-up:
Planned recruitment (number of patients):
Number eligible:
Number randomised:
Number completing trial:
Recruitment period:
Start Finish Not stated
Number analysed:
Section 4: participants
Inclusion criteria
Did all patients have a diagnosis of pancreatic carcinoma?
Yes No
If NO, are outcome data available separately for patients with pancreatic carcinoma?
Yes No
If NO, contact authors?
Did all patients have a pathologically confirmed diagnosis of pancreatic carcinoma
Yes No
If NO, is outcome available separately for patients in whom pathological diagnosis was made?
Yes No
If NO, contact authors?Appendix 2
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Participants Total Control Treatment 1 Treatment 2 Treatment 3
Number randomised
Number with 
pancreatic cancer
Number with histo-
logical confirmation
Mean/median age
Age range
Patients undergoing 
biliary stenting
Surgical treatment for 
pancreatic cancer
Disease extent Total Control Treatment 1 Treatment 2 Treatment 3
Locally advanced
Metastatic
Relapsed
Section 5: interventions
Details of regimen used Control Treatment 1 Treatment 2 Treatment 3
Drug/s
Dose/s
Schedule
RT doseHealth Technology Assessment 2001; Vol. 5: No. 24
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Co-interventions
Was any co-intervention used prior to stated drug therapy?
YesN oN ot stated
If YES, please give details:
Was any concomitant therapeutic drug therapy used?
YesN oN ot stated
If YES, please give details:
Was any drug used post-intervention?
YesN oN ot stated
If YES, please give details:
Section 6: toxicity
Outcome Scale %/# %/# %/# %/#
used patients and patients and patients and patients and
severity for severity for severity for severity for
control treatment 1 treatment 2 treatment 3
Laboratory
Haematological
Anaemia
Leucopenia
Neutropenia
Thrombocytopenia
Hepatic
ALT
AST
Alkaline phosphatase
Bilirubin
Renal
Proteinuria
Haematuria
BUN
Creatinine
Non-laboratory
Nausea and vomiting
Pain
Fever
Rash
Dyspnoea
Constipation
Diarrhoea
Haemorrhage
Infection
Alopecia
Stomatitis
Somnolence
Paraesthesias
OtherAppendix 2
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Were causes of death given?
Yes No
If YES, please give details of cause and number per treatment group:
Cause of death Control Treatment 1 Treatment 2
Treatment related
Malignancy related
Other
Section 7: quality of life
Method used to calculate quality of life scores?
Who assessed quality of life?
Patient Doctor More than one individual
Details:
Outcome Scale used Control Treatment 1 Treatment 2 Treatment 3
Global QoL
Analgesic consumption
Pain intensity
Global pain
Performance status
Clinical benefit response
Section 8: drop-outs and withdrawals
Are numbers and reasons for drop-out and withdrawals described?
Yes No
Control Treatment 1 Treatment 2 Treatment 3
Number originally randomised
Number of losses to follow-up 
at end of treatment period
Number analysed
Reason 1
Reason 2
Reason 3Health Technology Assessment 2001; Vol. 5: No. 24
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Appendix 3
Tables 3–22
TABLE 3  Gemcitabine as an adjuvant treatment (RCT)
Reference Study type Overall  Interventions Participants No. entered  Results
Jadad (evaluated)
score
IL-2, interleukin-2; IFN, interferon; CR, complete response; PD, progressive disease
Lygidakis et al.,
1998
19
RCT
No description of
method of
randomisation used
No description of 
blinding and none
appears to have
been carried out
Withdrawals and 
drop-outs described
1 A = curative surgery alone
B = curative surgery and gemcitabine
(1000 mg/m
2), carboplatin (200
mg/m
2), mitoxantrone (0.2 g/kg) and
immunotherapy (1 ml IL-2 and 0.5 ml
γ-IFN) followed by 5-day transsplenic
and 5-day transtumoral
immunotherapy course with the
same agents; this course was
repeated at 2-month intervals 
during first postoperative year and
every 3 months thereafter
C = palliative surgery alone
D = palliative surgery and the same
drug regimen as in A
512 patients with
pancreatic cancer
A = 106
(106)
B = 168 (168)
C = 103
(103)
D = 135
(135)
Mean survival
(months)
A = 14
B = 32
C = 6.8
D = 16
Lygidakis et al.,
1998
20
RCT
No description of
method of
randomisation
No description of
blinding and none
appears to have
been carried out
No description of
withdrawals or
drop-outs
2 A = lipiodol (10 ml), 58% urografin 
(2 ml) suspended with docetaxel
(100 mg/m
2), gemcitabine (1000
mg/m
2) and carboplatin (200 mg/m
2)
via catheter in the superior
mesenteric artery; catheter then
repositioned in the splenic artery and
a 10-day course of immunotherapy
was administered using proleukin 
(1 ml 18 × 10
6) suspended in lipiodol 
(1.5 ml) and urografin (0.5 ml) for 
10 consecutive days; further
immunotherapy for 10 days 
commencing 20 days after 
subtotal pancreatectomy
B = surgery alone
26 patients with
histologically
confirmed
resectable
pancreatic cancer
A = 14 (14)
B = 12 (12)
CR (no.
patients)
A = 11
B = 3
PD (no.
patients)
A = 3
B = 9
p <0.01
Survival (no.
patients)
A = 14
B = 6
p < 0.01Appendix 3
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TABLE 4  Gemcitabine as a single agent therapy (RCT)
Reference Study type Overall  Interventions Participants No. entered  Results
Jadad (evaluated)
score
continued
Burris et al.,
1997
13
RCT
No description 
of method of
randomisation
Treatment was
single blind as 
study drug was 
not blinded to
investigator because
a rash was a
potential side-effect
of both 5-FU and
gemcitabine
Nos and reasons
for drop-outs and
withdrawals were
stated
2 A = gemcitabine (1000 mg/m
2) 
weekly for 7 weeks then 1 week rest;
then once weekly for 3 weeks out of
every 4
B = 5-FU (600 mg/m
2 i.v. bolus) once
weekly; one cycle every 4 weeks
126 patients with
pathologically
confirmed locally
advanced or
metastatic 
pancreatic cancer
126 (126) Median survival
(months)
A = 5.65
B = 4.41
p = 0.0025
1-year survival
(%)
A = 18
B = 2
p = 0.0025
Median
progression-free
survival
(months)
A = 2.33
B = 0.92
p = 0.0002
Time to
treatment
failure (months)
A = 2.04
B = 0.92
CBR (%)
A = 23.8
B = 4.8
p = 0.0022
Cantore et al.,
2000
18
[Abstract only]
RCT
No description of
method of 
randomisation
No description of
method of blinding
Drop-outs and
withdrawals
described
1 A = gemcitabine (1000 mg/m
2) 
weekly for 7 weeks and 1 week rest;
then weekly for 3 out of every 4
weeks
B = 5-FU (400 mg/m
2) and FA 
(20 mg/m
2) on days 1–5 every 4
weeks for 6 cycles
C = 5-FU (100 mg/m
2), FA 
(100 mg/m
2), epirubicin (60 mg/m
2)
and carboplatin (300 mg/m
2) infused
intra-arterially every 3 weeks for 
6 cycles
106 patients with
unresectable 
pancreatic cancer
A = 35 (31)
B = 34 (31)
C = 37 (35)
Preliminary
report
Results not yet
reported
Moore et al.,
2000
22
[Abstract only]
RCT
No description of
method of
randomisation
No description of
method of blinding
No description of
drop-outs and
withdrawals
1 A = gemcitabine (1000 mg/m
2)
weekly for 7 out of 8 weeks and then
weekly for 3 out of every 4 weeks
B = BAY12-9566 (80 mg p.o.) 
continuously
277 patients with
pancreatic cancer
277 (277) Median survival
(months)
A = 6.4
B = 3.2
p = 0.0001
Median progres-
sion-free
survival (months)
A = 3.54
B = 1.77
p = 0.012
Rosemurgy et al.,
1999
21
[Abstract; British
Biotech press
release only]
RCT
No description of
method of
randomisation used
No description of
blinding
No description of
withdrawals or
drop-outs
2 A = gemcitabine (1000 mg/m
2 per
day) weekly for 7 weeks and 1 week
rest; then weekly for 3 weeks out of 
every 4
B = marimistat (5 mg/day) b.d.
C = marimistat (10 mg/day) b.d.
D = marimistat (25 mg/day) b.d.
414 patients with
pathologically
confirmed locally
advanced or
metastatic 
pancreatic cancer
414 
(A = 104,
B = 105,
C = 102,
D = 103)
No significant
difference in 
survival
Median
survival (days)
A = 167
B = 110.5
C = 105
D = 125Health Technology Assessment 2001; Vol. 5: No. 24
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TABLE 4 contd  Gemcitabine as a single agent therapy (RCT)
Reference Study type Overall  Interventions Participants No. entered  Results
Jadad (evaluated)
score
FA, folinic acid
British Biotech,
2000
17
[Press release
only]
RCT
No description of
method of 
randomisation
Double blind and
placebo controlled
No description of
withdrawals or
drop-outs
2 A = gemcitabine (1000 mg/m
2) and
placebo (10 mg p.o. b.d.)
B = gemcitabine (1000 mg/m
2) and
marimistat (10 mg p.o. b.d.)
239 patients with
pathologically
confirmed 
pancreatic cancer
239 (239 but
no info. about
nos in each
arm)
No significant
difference in 
survival
No significant
difference in
QoL
TABLE 5  Additional reports: gemcitabine as a single agent therapy
Reference Study type Interventions Participants No. entered  Results
(evaluated)
continued
Aykan et al.,
2000
23
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) weekly
for 7 weeks and 1 week rest; then
for 3 weeks out of every 4 until
relapse or intolerable toxicity
14 patients with 
locally advanced or
metastatic pancreatic
cancer
14 (14) Median survival = 
6 months
PR = 1 patient
CR = 1 patient
Overall response rate 
= 14%
Carmichael et al.,
1996
37
Phase II Gemcitabine (800 mg/m
2 or 
1000 mg/m
2) once a week for 
3 weeks followed by 1 week rest
Dose increased by up to 20% if 
no toxicity
34 patients with
pathologically 
confirmed locally
advanced or 
metastatic pancreatic
cancer
34 (32) Median survival = 
6.3 months
Improvement in
performance status = 17%
Improvement in analgesic
requirement = 7.4%
Improvement in pain score
= 28.6%
Improvement in nausea =
27.3%
Casper et al.,
1994
24
Phase II Gemcitabine (800 mg/m
2
per week) for 3 weeks then 
1 week rest
Dose reduced for
myelosuppression and escalated in
absence of toxicity
44 patients with
pathologically 
confirmed locally
advanced or 
metastatic pancreatic
cancer
44 (44) Median survival = 5.6
months
1-year survival = 23%
Median progression-free
survival = 4 months
Overall response rate =
11%
Casper et al.,
1991
25
[Abstract only]
Multicentre
Phase II
Gemcitabine (800 mg/m
2 i.v.)
weekly for 3 weeks every 28 days
43 patients with 
locally advanced or
metastatic pancreatic
cancer
43 (39) PR = 13%
SD = 38%
MR = 8%
Crino et al.,
1997
26
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) once a
week for 7 weeks and 1 week rest;
then once weekly for 3 weeks out
of every 4
24 patients with 
locally advanced or
metastatic pancreatic
cancer
24 (24) PR = 16%
SD = 41%
PD = 41%Appendix 3
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TABLE 5 contd  Additional reports: gemcitabine as a single agent therapy
Reference Study type Interventions Participants No. entered  Results
(evaluated)
continued
Eickhoff et al.,
2000
39
[Abstract only]
Retrospective
cohort study
A = gemcitabine (1000 mg/m
2
on days 1 and 8 every 3 weeks
B = 5-FU (500 mg/m
2) and α-IFN 
(6 × 10
6 i.u.); 1 cycle every 
6 weeks
65 patients with 
inoperable pancreatic
carcinoma
A = 32
B = 33
(30 evaluated for
CBR in each
group; objective
response
evaluated in 28
patients 
in A and 
30 in B)
Overall survival (%)
A = 23
B = 28
Median survival
(months)
A = 8.5
B = 10.2
CR (no.)
A = 1
B = 4
PR (no.)
A = 5
B = 4
Overall response (%)
A = 21
B = 26
Klein et al.,
2000
38
Retrospective
cohort study
A = gemcitabine (1000 mg/m
2)
weekly for 3 weeks out of every 4
B = 2 dose schedules of 5-FU and
leucovorin (low-dose leucovorin
20 mg/m
2 i.v. bolus and 5-FU 370
mg/m
2 for 5 consecutive days
every 28 days; or leucovorin 200
mg/m
2 and 5-FU 900 mg/m
2 every
2 weeks)
82 patients with
pathologically
confirmed advanced,
metastatic or relapsed
pancreatic cancer
A = 35
B = 47
(60 evaluated for
objective
response, 22 for
toxicity, 85 for
CBR, and 82 for
survival)
1-year survival (%)
A = 23
B = 32
CBR (%)
A = 48
B = 19
Objective response (%)
A = 9
B = 4
Kurtz et al.,
1999
27
Multicentre
Phase II
Gemcitabine (800–1000 mg/m
2)
weekly for 3 out of every 4 weeks
74 patients with 
surgically unresectable,
metastatic or relapsed
pancreatic cancer
74 (varies
according to
outcome)
Overall survival = 
5 months
CBR = 48%
Progression-free survival =
2.5 months
PR = 2 patients
SD = 18 patients
PD = 24 patients
Petrovic et al.,
1998
28
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) weekly
for 7 weeks and 1 week rest; then
once weekly for 3 weeks out of
every 4
54 patients with 
pancreatic cancer
54 (11) Median survival = 
6.65 months
1-year survival = 26%
CBR = 33%
Rothenberg et al.,
1996
29
Multicentre
Phase II
Gemcitabine (1000 mg/m
2) weekly
for 7 weeks and 1 week rest; then
for 3 weeks out of every 4 
74 patients with
metastatic pancreatic
cancer that was
refractory to and had
progressed despite the
administration of 5-FU
74 (63 evaluable
for CBR and 54
for response)
Median survival = 4
months
1-year survival = 4%
CBR = 27%
PR = 11%
SD= 30%
Roznowski and
Ramlau, 1999
30
[English abstract
only]
Phase II Gemcitabine (1000 mg/m
2) weekly
for 7 weeks and 1 week rest; then
weekly for 3 weeks out of every 4
12 patients with
pathologically 
confirmed locally
advanced or
metastatic pancreatic
cancer
12 (12) Median survival = 
21 weeks
Time to treatment failure
= 15.7 weeks
PR = 10%
SD = 50%
Scheithauer et al.,
1999
31
[Abstract only]
Phase II Gemcitabine (2200 mg/m
2) every 
2 weeks for 6 months
38 patients with
metastatic pancreatic
cancer
38 (28) Median survival >6.5 months
CBR = 35%
Median progression-free
survival = 4.5 months
Objective response rate =
28%Health Technology Assessment 2001; Vol. 5: No. 24
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TABLE 5 contd  Additional reports: gemcitabine as a single agent therapy
Reference Study type Interventions Participants No. entered  Results
(evaluated)
PR, partial response; CR, complete response; SD, stable disease; MR, minor response; PD, progressive disease; CBR, clinical benefit response
Spagnuolo et al.,
1999
32
[Abstract only]
Phase II Gemcitabine (1500 mg/m
2) every
28 days delivered in 30 min
through superselective arterial or 
coeliac infusion
10 patients with
locally advanced or
metastatic pancreatic
cancer
10 (10) CBR = 7 patients
PR = 2 patients
MR= 4 patients
Storniolo et al.,
1999
33
Retrospective
investigational
new drug study
Gemcitabine (1000 mg/m
2) once
weekly for 7 weeks and 1 week
rest; then once weekly for 
3 weeks out of every 4 until
disease progression or
unacceptable toxicity
3023 patients with
pathologically 
confirmed pancreatic
cancer
3023 (varied for
any given end-
point based on
no. of completed
records returned
by the investi-
gators: 2015 for
dosage, 2380 for
survival, 2012 for
disease
progression, 982
for tumour
response, 1694
for symptom
benefit and 2140
for discontin-
uation data)
Median survival = 
4.8 months
6-month survival = 41%
9-month survival = 22%
1-year survival = 15%
Median time to disease
progression = 2.7 months
PR = 10.6% 
CR = 1.4%
Overall response rate =
12.0%
DRSI = 18.4%
Tempero et al.,
1999
34
[Abstract only]
Randomised
Phase II
A = gemcitabine (2200 mg/m
2)
over a standard 30 min infusion
weekly for 3 weeks out of every 4
B = gemcitabine (1500 mg/m
2) at a
rate of 10 mg/m
2 per min weekly
for 3 weeks out of every 4
93 patients with
pathological 
confirmation of 
pancreatic cancer
93 (67) Median survival
(months)
A = 4.7
B = 6.1
1-year survival (%)
A = 0
B = 23
Time to treatment 
failure (months)
A = 1.9
B = 2.2
Objective response rate
(%)
A = 2.7
B = 16.6
Ulrich-Pur et al.,
2000
35
Phase II Gemcitabine (2200 mg/m
2) on days
1 and 15 repeated every 4 weeks;
continued for patients achieving
objective response or SD until 
6 courses completed
43 patients with
pathologically 
confirmed metastatic
or relapsed pancreatic
cancer
43 (43 evaluable
overall and 36 for
CBR)
Median survival = 8.8
months
1-year survival = 26.3%
CBR = 44%
Median progression-free
survival = 5.3 months
PR = 8 patients
CR = 1 patient
SD = 42%
Overall response rate =
21%
Weissman and
Ludwig, 1999
36
[Abstract only]
Phase II Gemcitabine (1200 mg/m
2) as a 
3-min infusion into intra-arterial
catheter (coeliac artery for
pancreatic cancer) or hepatic
artery for cholangiocarcinoma;
1 cycle every 4 weeks
15 patients with 
inoperable pancreatic
cancer
15 (15) Median survival = 5.5
months
CR = 2 patients
SD = 4 patientsAppendix 3
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TABLE 6  Additional reports: gemcitabine and 5-FU
Reference Study type Interventions Participants No. entered  Results
(evaluated)
continued
Anchisi et al.,
2000
40
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2 on days 1
and 8) and continuous infusion 5-FU
(200 mg/m
2 per day on days 1 to 15); 1
cycle every 3 weeks
19 patients with
pathologically 
confirmed locally
advanced, metastatic
or relapsed pancreatic
cancer
19 (17) Median survival = 
21 weeks
PR = 25%
SD = 25%
Overall response rate =
31%
Berlin et al.,
2000
41
Phase II Gemcitabine (1000 mg/m
2) and 5-FU
(600 mg/m
2 i.v. bolus) weekly for
3 weeks out of every 4; protocol 
complete after 8 4-week cycles
37 patients with
metastatic pancreatic
cancer
37 (36) Median survival = 
4.4 months
1-year survival = 8.6
months
PR = 14%
Borner et al.,
1998
42
[Abstract only]
Phase II ongoing Gemcitabine (1000 mg/m
2) and
continuous infusion 5-FU (200 mg/m
2)
weekly for 3 weeks every 28 days
14 patients with 
locally advanced or
metastatic pancreatic
cancer
14 (12) PR = 25%
MR = 25%
SD = 33%
PD = 17%
Cascinu et al.,
1999
43
Multicentre
Phase II
Gemcitabine (1000 mg/m
2) and 5-FU
(600 mg/m
2) weekly for 3 weeks out 
of every 4
54 patients with
pathologically 
confirmed locally
advanced or metastatic
pancreatic cancer
54 (54) Median survival = 
7 months
CBR = 51%
PR = 2 patients
SD = 34 patients
Cortes-Funes et
al., 1998
44
[Abstract only]
Phase I–II Gemcitabine at 5 different dose levels
(700, 800, 900, 1000, 1100 mg/m
2) and
5-FU (200 mg/m
2 per day) weekly for 3
weeks out of every 4
26 patients with 
pancreatic cancer
26 (24
overall;
20 CBR)
Overall survival = 
10.4 months
CBR = 55%
PR = 3 patients
CR = 1 patients
Overall response rate =
16%
de Gusmao et al.,
1998
45
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2 per day) and
5-FU (500 mg/m
2 per day) weekly for 3
weeks; 1 cycle every 4 weeks for a
maximum of 8 cycles
12 patients with
pancreatic cancer (+2
with advanced biliary
tract carcinoma)
14 (14) Median survival = 
13 months
Objective response = 
6 patients
Hidalgo et al.,
1999
46
Phase I–II Gemcitabine (700 mg/m
2) weekly for 
3 weeks out of every 4 (dose escalated
by 100 mg/m
2 in successive cohorts of
patients to a maximum of 6 cycles) and
5-FU (200 mg/m
2)
26 patients with
pathologically 
confirmed locally
advanced, metastatic
or relapsed pancreatic
cancer
26 (26
overall;
22 CBR)
1-year survival = 39.5%
CBR = 45%
Median progression-free
survival = 7.4 months
PR = 4 patients
CR = 1 patient
Improvement of disease
symptoms = 10 patients
Jovtis et al.,
1999
47
[Abstract only]
Multicentre
Phase II
Gemcitabine (1000 mg/m
2), 5-FU (600
mg/m
2) and leucovorin (25 mg/m
2)
weekly for 3 weeks out of every 4
18 patients with 
locally advanced or
metastatic pancreatic
cancer
18 (18) Median survival = 
11 months
PR = 4 patients
SD = 11 patients
Lencioni et al.,
2000
48
[Abstract only]
Phase I–II Gemcitabine (1000 mg/m
2 i.v.),
leucovorin (250 mg/m
2 i.v.) and 5-FU 
(3 doses of 1400, 2000 and 2600
mg/m
2) weekly for 3 weeks out of
every 4
22 patients with
pathologically
confirmed locally
advanced or metastatic
pancreatic cancer
22 (21
evaluable for
response and
16 for CBR)
CBR 9/16 patients
PR = 1 patient
Objective response = 1
patient
SD = 11 patientsHealth Technology Assessment 2001; Vol. 5: No. 24
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TABLE 6 contd  Additional reports: gemcitabine and 5-FU
Reference Study type Interventions Participants No. entered  Results
(evaluated)
continued
Louvet et al.,
1999
49
[Abstract only]
Multicentre
Phase II ongoing
FOLFUGEM:
Leucovorin 400 mg/m
2 2-h i.v. infusion,
followed by 5-FU 400 mg/m
2 bolus and
3000 mg/m
2 48-h infusion (first 24
patients) or 2000 mg/m
2 (remaining 24
patients)
Gemcitabine day 3 after 5-FU infusion,
at dose 1000 mg/m
2 (cycles 1 and 2),
then increased to 1250 mg/m
2 (cycles
3 and 4) and to 1500 mg/m
2 (cycle 5
and following cycles) when toxicity was
<WHO grade 3
Treatment administered every 2 weeks
(or delayed to every 3 weeks if non-
adequate haematological parameters)
until progression in metastatic disease
(30 patients), or for 6 courses followed
by chemoradiation in locally advanced
disease (18 patients)
48 patients with
locally advanced or
metastatic pancreatic
cancer
48 (48) 1-year survival = 38%
Median progression-free
survival = 4.5 months
Matano et al.,
2000
50
Phase II Gemcitabine (1000 mg/m
2) days 1, 8
and 15 and 5-FU (500 mg/m
2) days
1–5; 1 cycle every 28 days with a 
50% dose reduction if haematological
toxicity
11 patients with
pathologically 
confirmed metastatic
pancreatic cancer
11 (11) CBR = 64%
Median progression-free
survival = 26.8 weeks
Oettle et al.,
1999
51
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2), 5-FU 
(750 mg/m
2) and FA (200 mg/m
2) days
1, 8, 15 and 22, followed by a break of
2 weeks
17 patients with
pancreatic cancer
17 (17) Median progression-free
survival = 7.5+ months
Pastorelli et al.,
2000
57
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2 i.v.) and 
5-FU (600 mg/m
2 i.v.) days 1, 8 and 15,
every 28 days
24 patients with
advanced pancreatic
cancer
24 (24 for
toxicity and
22 for
response)
Median survival = 7.5
months
PR = 13%
SD = 22.4%
Polyzos et al.,
2000
52
[Abstract only]
Phase II Gemcitabine (750 mg/m
2) days 1 and 8,
5-FU (350 mg/m
2) days 1, 2, 3, 7 and 8,
and leucovorin (350 mg/m
2) days 1, 2,
3, 7 and 8; 1 cycle every 4 weeks
40 patients with 
locally advanced or
metastatic pancreatic
cancer
40 (40) 1-year survival = 25%
Median progression-free
survival = 5 months
Objective response rate =
20%
SD = 38%
PD = 43%
Riedel et al.,
2000
53
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) and 5-FU
(2000 mg/m
2) weekly for 3 weeks then
1 week rest
15 patients with
metastatic pancreatic
cancer
15 (15) 1-year survival = 36%
PR = 14%
SD = 50%
PD = 36%
Rodriguez-
Lescure et al.,
1999
54
[Abstract only]
Phase I–II Gemcitabine (800, 1000, 1200 and 1400
mg/m
2) and 5-FU (3 g/m
2) weekly for 
3 weeks every 28 days
23 patients with 
pancreatic cancer
23 (21) Median survival = 
22 weeks
CBR = 57%
Median progression-free
survival = 12 weeks
PR = 3 patients
CR = 1 patient
SD = 33%
Overall response rate =
19%
Shulman et al.,
2000
55
[Abstract only]
Phase II Gemcitabine (600 mg/m
2) days 1, 8 and
15 and 5-FU (200 mg/m
2) daily for 
21 days; 1 cycle every 28 days
15 patients with
pathologically 
confirmed pancreatic
cancer
15 (?) Median survival = 
8 months
Median progression-free
survival = 3 months
PR = 13%
SD = 40%
PD = 40%Appendix 3
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TABLE 6 contd  Additional reports: gemcitabine and 5-FU
Reference Study type Interventions Participants No. entered  Results
(evaluated)
Tarantini et al.,
1999
56
[Abstract only]
Phase I–II 
ongoing
A = gemcitabine (1000 mg/m
2) and 5-FU
(1000 mg/m
2) days 1, 8 and 15, every 
4 weeks
B = gemcitabine (1000 mg/m
2) and 5-FU
(2000 mg/m
2 24-h continuous infusion)
days 1, 8 and 15 every 4 weeks
C = gemcitabine (1200 mg/m
2) and 5-FU
(2250 mg/m
2 i.v. 24-h continuous
infusion) days 1,8 and 15 every 4 weeks
17 patients with
metastatic pancreatic
cancer
17 (17
evaluable for
toxicity and
14 for
response)
CBR = 58.8%
PR = 28.6%
TABLE 7  Additional reports: gemcitabine and docetaxel
Reference Study type Interventions Participants No. entered  Results
(evaluated)
G-CSF, granulocyte-colony stimulating factor; rhG-CSF, recombinant human granulocyte-colony stimulating factor
Androulakis et al.,
1999
58
[Abstract only]
Multicentre
Phase II
Gemcitabine (1000 mg/m
2) days 1 and
8, docetaxel (100 mg/m
2) day 8 and 
G-CSF (150 igr/m
2 s.c.) days 1–15;
1 cycle every 3 weeks
56 patients with 
locally advanced or
metastatic pancreatic
cancer
56 (43 for
response and
56 for 
toxicity)
Median survival = 
8 months
1-year survival = 32%
Median progression-free
survival = 3 months
Time to treatment failure
= 9 months
Cascinu et al.,
1999
59
Phase I–II A = (Phase I) gemcitabine (1000
mg/m
2) and docetaxel (70 mg/m
2); dose
escalation of docetaxel if no dose
limiting toxicities occurred in 1 of 3 or
2 of 6 patients
B = (Phase II) gemcitabine (1000 mg/m
2
once weekly for 2 consecutive weeks
every 3 weeks) and docetaxel (70
mg/m
2) once in week 2
27 patients with
pathologically 
confirmed locally
advanced, metastatic
cancer
27 (27) Median survival = 
5.4 months
Median progression-free
survival = 3 months
Clark et al.,
2000
60
[Abstract only]
Phase II Gemcitabine (600 mg/m
2) days 1, 8 and
15, and docetaxel (60 mg/m
2) day 1;
1 cycle every 28 days
34 patients with
metastatic pancreatic
cancer
34 (24) PR = 1 patient
CR = 1 patient
Objective response 
rate = 8%
Jacobs et al.,
2000
61
[Abstract only]
Phase I–II A = gemcitabine (800 mg/m
2) days 1, 8
and 15 and docetaxel (75 mg/m
2) 
day 1; 1 cycle every 28 days
B = gemcitabine (1000 mg/m
2)d a ys 1
and 8 or docetaxel (40 mg/m
2) days 1
and 8; 1 cycle every 21 days
29 patients with
pathologically 
confirmed locally
advanced or
metastatic pancreatic
cancer
29 (25) Median survival = not yet
reached
Time to treatment failure
= 5.25 months
PR = 28%
MR or SD = 40%
Kakolyris et al.,
1999
62
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) days 1 and
8, docetaxel (100 mg/m
2) day 8, every 3
weeks and rhG-CSF (150 igr/m
2
d9–d15)
38 patients with 
pancreatic cancer
38 (38 for
toxicity and
27 for
response)
Median survival = 
7 months
1-year survival = 22%
Time to progression = 
7 months
PR = 7.4%
SD = 33.3%
PD = 59%Health Technology Assessment 2001; Vol. 5: No. 24
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TABLE 8  Additional reports: gemcitabine and platinum compounds
Reference Study type Interventions Participants No. entered  Results
(evaluated)
Colucci et al.,
1998
63
[Abstract only]
Randomised
Phase II
A = gemcitabine (1000 mg/m
2) weekly
for 7 weeks out of 8 and then weekly
for 3 weeks out of every 4
B = gemcitabine (1000 mg/m
2) and
cisplatin (25 mg/m
2) weekly for 
7 weeks out of 8, and then weekly for 
3 weeks out of every 4
103 patients with
advanced pancreatic
cancer
A = 51 (30)
B = 52 (32)
CBR (%)
A = 45 (10/22)
B = 38 (9/24)
Overall response rate (%)
A = 10
B = 31
Heinemann et al.,
1997
64
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) days 1, 8
and 15, and cisplatin (50 mg/m
2) days 1
and 15; 1 cycle every 28 days
41 patients with 
locally advanced or
metastatic pancreatic
cancer
41 (37) Median survival = 
8.6 months
PR = 2 patients
CR = 1 patient
SD = 18 patients
Heinemann et al.,
1999
65
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2)d a ys 1 and
15, and cisplatin (50 mg/m
2)d a ys 1 
and 15
41 patients with
locally advanced or
metastatic pancreatic
cancer
41 (35) Median survival = 
8.3 months
1-year survival = 28%
Median progression-free
survival = 4.3 months
PR = 3 patients
CR = 1 patient
SD = 6 patients
Overall response rate =
11.5%
Philip et al.,
1999
66
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) days 1, 8
and 15, and cisplatin (50 mg/m
2) days 
1 and 15; 1 cycle every 28 days
27 patients with
pathologically 
confirmed locally
advanced or
metastatic pancreatic
cancer
27 (22
evaluable for
response; 26
for toxicity)
Median survival = 
7.4 months
Median progression-free
survival = 6.2 months
PR = 6 patients
CR = 2 patients
Overall response rate =
36.4%
TABLE 9  Additional reports: gemcitabine and MMC
Reference Study type Interventions Participants No. entered  Results
(evaluated)
Bazin et al.,
1999
67
[Abstract only]
Phase I–II A = gemcitabine (1000 mg/m
2) days 1,
8 and 15, and MMC (5–10 mg/m
2) day
1, with a 2-week rest between cycles
B = gemcitabine (1000 mg/m
2) days 1,
8, 21 and 29, and MMC (8 mg/m
2) day
1, with a 2-week rest between cycles
25 patients with 
pancreatic cancer
25 (23 for
toxicity and
21 for 
efficacy)
CBR = 60%
Objective response 
rate = 38%
Klapdor et al.,
1999
68
Phase II MMC (10–15 mg/m
2) day 1 and
gemcitabine (800 mg/m
2) days 1, 8 
and 15;
1 cycle every 3 weeks
28 patients with 
locally advanced,
metastatic or relapsed
pancreatic cancer
28 (28) Median survival = 
9 months
Median progression-free
survival = 7.5 months
PR = 43%
CR = 3%
SD = 11%
PD = 18%
TABLE 10  Additional reports: gemcitabine and other chemotherapy combinations
Reference Study type Interventions Participants No. entered  Results
(evaluated)
continued
De Castro et al.,
2000
69
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) days 1, 8
and 15, leucovorin (250 mg/m
2 i.v.) day
1, oral (leucovorin (7.5 mg/12 h) days
2–14, and UFT (390 mg/m
2) in 2 doses
days 1–14; 1 course every 28 days,
minimum 3 courses
42 patients with 
locally advanced, or
metastatic pancreatic
cancer
42 (38) CBR = 47%
PR = 16%
SD = 39%
PD = 45%Appendix 3
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TABLE 10 contd  Additional reports: gemcitabine and other chemotherapy combinations
Reference Study type Interventions Participants No. entered  Results
(evaluated)
UFT, uracil-tegafur
Feliu et al., 1999
70
[Abstract only]
Phase II ongoing Gemcitabine (1500 mg/m
2) days 1 and
14, i.v. leucovorin (250 mg/m
2 i.v.) day
1, oral leucovorin every 12 h days
2–15, and UFT (390 mg/m
2 per day
days 1–14; 1 cycle every 28 days,
minimum 3 cycles
25 patients with 
locally advanced or
metastatic pancreatic
cancer
25 (22) Median survival = 
8 months
CBR = 59%
Time to treatment failure
= 6 months
PR = 14%
SD = 54%
PD = 32%
Jacobs et al.,
1999
71
[Abstract only]
Phase II Gemcitabine (800 mg/m
2) days 1, 8 and
15, and taxotere (75 mg/m
2) day 1
12 patients with
pathologically 
confirmed locally
advanced or metastatic
pancreatic cancer)
12 (9) Median progression-free
survival = 2 months
PR = 3 patients (33%)
SD = 2 patients (22%)
Raderer et al.,
1998
72
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) days 1, 8
and 15, epirubicin (60 mg/m
2) day 1,
and G-CSF (5 µg/kg per day s.c.) 
days 2–6; 1 course every 5 weeks
55 patients with
pancreatic cancer
55 (47) CBR = 40%
Time to treatment failure
= 3.6 months
SD = 40%
Objective response 
rate = 19%
Reni et al., 1999
73
[Abstract only]
4 consecutive
prospective 
clinical trials
A = 5-FU (600 mg/m
2) days 1, 8, 29 and
36, adriamycin (30 mg/m
2) days 1 and
29, and MMC (10 mg/m
2) day 1
B = epirubicin (50 mg/m
2) day 1, and 
5-FU (1 g/m
2) days 1–5
C = as B but with cisplatin (50 mg/m
2)
day 1
D = cisplatin 40 mg/m
2 and epirubicin
(40 mg/m
2) day 1,4-FU (200 mg/m
2)
daily, and gemcitabine (600 mg/m
2)
days 1–8
114 patients with
pathologically 
confirmed metastatic
pancreatic cancer
A = 22 (22)
B = 44 (44)
C = 22 (22)
D = 29 (29)
Median survival
(months)
A = 5
B = 5
C = 7
D = 6.5+
1-year survival (%)
A = 9
B = 9
C = 5
D = 27?
6-Month progression-
free survival (%)
A = 5
B = 10
C = 29
D = 42?
Time to treatment 
failure (months)
A = 2
B = 2.5
C = 2.5
D = 5
PR (%)
A = 9
B = 2.5
C = 13.5
D = 62
Stathopoulos et
al., 2000
74
[Abstract only]
Phase II Gemcitabine (900 mg/m
2) days 1 and 8,
and irinotecan (300 mg/m
2) day 8;
every 3 weeks
28 patients with 
pancreatic cancer
28 (28
evaluable for
toxicity; 20
for response)
Median survival not yet
reached
Time to treatment failure
= 30 weeks
Villa and Reni
1999
75
[Abstract only]
Phase II study Cisplatin (40 mg/m
2) day 1, epirubicin
(40 mg/m
2)d ay 1, and gemcitabine 
(600 mg/m
2) days 1 and 8, every 
4 weeks; and 5-FU (200 mg/m
2
per day) daily
49 patients with
metastatic pancreatic
cancer
49 (43 for
response; 22
for CBR)
1-year survival = 40%
Median survival = 9.4
months
PR = 89%
MR = 8%
PD = 9%
SD = 14%
CBR = 78%Health Technology Assessment 2001; Vol. 5: No. 24
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TABLE 11  Additional reports: gemcitabine in chemoradiation
Reference Study type Interventions Participants No. entered  Results
(evaluated)
RT,r adiotherapy
Antonisse et al.,
1999
76
[Abstract only]
Phase II Gemcitabine (300 mg/m
2 days 1, 8 and
15, and 1000 mg/m
2 weekly from day
22), and RT to the macroscopic
tumour in 3 fractions on days 1, 8 
and 15
21 patients with 
pancreatic cancer
21 (21) Median survival = 
16.2 months
Reduction in CA19.9 =
82%
Palliation of pain = 72%
Reduction in analgesic
consumption = 73%
Epelbaum et al.,
2000
77
[Abstract only]
Phase II Gemcitabine (1000 mg/m
2) once 
weekly for 7 weeks; those who
demonstrated a CBR went on to
gemcitabine (400 mg/m
2) weekly for 
3 weeks every 28 days for 2 cycles
delivered concurrently with 50.4 Gy
RT in 1.8 Gy daily fractions;
gemcitabine re-escalated to 1000
mg/m
2 after RT as maintenance therapy
20 patients with 
locally advanced
pancreatic cancer
20 (20) Median survival = 
12 months
CBR = 10 (50%)
PR = 20%
Reyes-Vidal et al.,
2000
78
[Abstract only]
Phase II Gemcitabine (200, 225, 300 and 325
mg/m
2) for 5 weeks 4–8 hours prior to
RT;R T (4500 cGy) through 3 fields in
25 fractions over 5 weeks
14 patients with 
pancreatic cancer
14 (14) PR = 6 patients
CR = 2 patients
SD = 6 patients
Wilkowski et al.,
2000
79
[Abstract only]
Phase II Gemcitabine (300 mg/m
2) on RT days
1, 15 and 29, 5-FU (350 mg/m
2) on
each RT day; and RT in 1.8 Gy fractions
up to 45 Gy
13 patients with 
locally advanced or
relapsed pancreatic
cancer
13 Surgery offered 
subsequently to 5 patients
and 4 achieved a complete
resection
CA19.9 levels declined 
in 77%
Downstaging in 7/10 
primarily unresectable
patients
TABLE 12  Additional reports: gemcitabine and hormonal treatment
Reference Study type Interventions Participants No. entered  Results
(evaluated)
SMSpaLAR, somatostatin analogue octreotide
Caillouette et al.,
1999
80
[Abstract only]
Phase I–II SMSpaLAR (160 mg i.m.) every 
2 weeks for 4 injections and then
monthly, and gemcitabine 
(1000 mg/m
2 i.v.) weekly for 
3 weeks and then 1 week rest
19 patients with 
locally advanced or
metastatic pancreatic
cancer
19 (14) Median survival = 
18 weeks
PR = 1 patient
Tomao et al.,
1998
81
[Abstract only]
Phase II Gemcitabine (dosage not stated but
administered once a week for 7 weeks
then 1 week rest), and tamoxifen 
(daily continuously)
17 patients with
metastatic pancreatic
cancer
17 (17) CBR = 8 patients
PR = 1 patient
SD = 9 patients
TABLE 13  Gemcitabine as an adjuvant treatment (RCT)
Reference No. entered (evaluated)          Median survival (months)                        CR (%)
Lygidakis et al., 1998
19 512 (512) 14
32
6.8
16
Lygidakis et al., 1998
20 26 (26) 78
25Appendix 3
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TABLE 14  Gemcitabine as a single agent therapy (RCT)
Reference No. entered      Median survival    1-year survival        Median progression-free    PR (%)    CBR (%)
(evaluated)           (months)                  (%)                      survival (months)
Burris et al., 1998
13 126 (126) 5.65 18 2.33 5.4 23.8
4.41 2 0.92 0.0 4.8
Moore et al., 2000
22 277 (277) 6.4 3.54
[Abstract only] 3.2 1.77
Rosemurgy et al., 1999
21 414 (414)
[Abstract; British Biotech 
press release only]
British Biotech 2000
17 239 (239)
[Press release only]
TABLE 15  Additional reports: gemcitabine alone as a single agent therapy
Reference                            No. Median     1-year        Median          PR (%)      CR (%)     SD (%)      PD   Objective/   CBR
entered       survival     survival   progression-                                                       (%)     overall       (%)
(evaluated)   (months)       (%)             free                                                                      response
survival                                                                    rate (%)
(months)
Aykan et al., 2000
23 14 (14) 6 7 7 14
[Abstract only]
Carmichael et al., 1996
37
34 (32) 6.3
Casper et al., 1994
24 44 (44) 5.6 23 4 11
Casper et al., 1991
25 43 (39) 13 38
[Abstract only]
Crino et al., 1997
26 24 (24) 16 41 41
[Abstract only]
Eickhoff et al., 2000
39 65 (65; 5 1 21
[Abstract only]                     60 CBR)
Klein et al., 2000
38 82 (a)2 3 9 4 8
Kurtz et al., 1999
27 74 (a) 2.5 8 75 12 48
Petrovic et al., 1998
28 54 (11) 6.65 26 33
[Abstract only]
Rothenberg et al., 1996
29 74 (63 CBR; 4 4 11 30 27
54 response)
Roznowski and  12 (12) 5.25 10 50
Ramalu, 1999
30
[English abstract only]
Scheithauer et al., 1999
31 38 (28) >6.5 4.5 28 35
[Abstract only]
Spagnuolo et al., 1999
32 10 (10) 20 70
[Abstract only]
Storniolo et al., 1999
33 3023 (a) 4.8 15 2.7 10.6 1.4 12
Tempero et al., 1999
34 93 (67) 4.7 0 2.7
6.1 23 16.6
[Abstract only]
Ulrich-Pur et al., 1999
35 43 8.8 26.3 5.3 18.6 2.3 42 21 44
(43; 36 CBR)
Weissman and Ludwig, 15 (15) 5.5 13 27
[Abstract only] 1999
36
a No. evaluated varies according to outcomeHealth Technology Assessment 2001; Vol. 5: No. 24
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TABLE 16  Additional reports: gemcitabine and 5-FU
Reference                            No. Median     1-year        Median          PR (%)      CR (%)     SD (%)      PD   Objective/   CBR
entered       survival     survival   progression-                                                       (%)     overall       (%)
(evaluated)   (months)       (%)             free                                                                      response
survival                                                                     rate (%)
(months)
Anchisi et al., 2000
40 19 (17) 5.25 25 25 31
[Abstract only]
Berlin et al., 2000
41 37 (36) 4.4 14
Borner et al., 1998
42 14 (12) 25 33 17
[Abstract only]
Cascinu et al., 1999
43 54 (54) 7 4 63 51
Cortes-Funes et al., 1998
44 26 13 4 16 55
[Abstract only]                   (24; 20 CBR)
De Gusmao et al., 1998
45 14 (14) 13 50
[Abstract only]
Hidalgo et al., 1999
46 26 (26; 39.5 7.4 15 4 45
22 CBR)
Jovtis et al., 1999
47 18 (18) 11 22 61
[Abstract only]
Lencioni et al., 2000
48 22 5 52 56
[Abstract only]                  (21; 16 CBR)
Louvet et al., 1999
49 48 (48) 38 4.5
[Abstract only]
Matano et al., 2000
50 11 (11) 26.8 64
Oettle et al., 1999
51 17 (17) >7.5
[Abstract only]
Pastorelli et al., 2000
57 24 (22)  7.5 13 22.4
[Abstract only]                    
Polyzos et al., 2000
52 40 (40) 25 5 38 43 20
Riedel et al., 2000
53 15 (15) 36 14 50 36
[Abstract only]
Rodriguez-Lescure 23  (21) 5.5 3 14 5 33 19 57
et al., 1999
54
[Abstract only]
Shulman et al., 2000
55 15 (?) 8 3 13 40 40
[Abstract only]
Tarantini et al., 1999
56 17 (14) 29 59
[Abstract only]                  Appendix 3
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TABLE 17  Additional reports: gemcitabine and docetaxel
Reference                                   No. Median           1-year          Median        PR (%)       CR (%)       SD (%)   Objective/
entered           survival          survival      progression-                                                     overall
(evaluated)       (months)            (%)        free  survival                                                     response
(months)                                                         rate (%)
Androulakis et al., 1999
58 56 (43)  8 32 3
[Abstract only]
Cascinu et al., 1999
59 27 (27) 5.4 3
Clark et al., 2000
60 34 (24) 4 4 8
[Abstract only]
Jacobs et al., 2000
61 29 (25) 28 40
[Abstract only]
Kakolyris et al., 1999
62 38 (27) 7 22
[Abstract only]
TABLE 18  Additional reports: gemcitabine and platinum compounds
Reference                             No. Median       1-year          Median          PR (%)     CR (%)    SD (%)      Objective/    CBR
entered         survival       survival     progression-                                                      overall         (%)
(evaluated)     (months)         (%)              free                                                            response 
survival                                                         rate (%)
(months)
Colucci et al., 1999
63 103 (A = 30; A = 10 A = 45
[Abstract only]                      B = 32) B = 31 B = 38
Heinemann et al., 1997
64 41 (37) 8.6 5 3 49
[Abstract only]
Heinemann et al., 1999
65 41 (35) 8.3 28 4.3 9 3 17 11.5
[Abstract only]
Philip et al., 1999
66 27 (22) 7.4 6.2 27 9 36.4
[Abstract only]
TABLE 19  Additional reports: gemcitabine and MMC
Reference                             No. Median          Median          PR (%)     CR (%)    SD (%)     PD (%)   Objective/    CBR
entered          survival       progression-                                                                  overall         (%)
(evaluated)     (months)           free                                                                         response 
survival                                                                        rate (%)
(months)
Bazin et al., 1999
67 25 (21) 38 60
[Abstract only]
Klapdor et al., 1999
68 28 (28) 9 7.5 43 3 11 18
[Abstract only]Health Technology Assessment 2001; Vol. 5: No. 24
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TABLE 20  Additional reports: gemcitabine and other chemotherapy combinations
Reference                            No. Median     1-year        Median           PR (%)         SD (%)        PD (%)    Objective/   CBR
entered       survival     survival   progression-                                                              overall       (%)
(evaluated)   (months)       (%)             free                                                                   response
survival                                                                  rate (%)
(months)
de Castro et al., 2000
69 42 (38) 16 39 45 47
[Abstract only]
Feliu et al., 1999
70 25 (22) 8 14 54 32 59
[Abstract only]
Jacobs et al., 1999
71 12 (9) 2 33 22
[Abstract only]
Raderer et al., 1998
72 55 (47) 40 19 40
[Abstract only]
Reni et al., 1999
73 114 (114) 5 9 9
[Abstract only] 5 9 2.5
79 13.5
>6.5 27 62
Stathopoulos 28  (20)
et al., 2000
74
[Abstract only]
Villa and Reni, 1999
75 49 (43; 22  9.4 40 >9.4 89 14 9 78
[Abstract only]                     for CBR)
TABLE 21  Additional reports: gemcitabine in chemoradiation
Reference                             No. entered              Median survival           PR (%)             CR (%)            SD (%)          CBR (%)
(evaluated)                   (months)
Antonisse et al., 1999
76 21 (21) 16.2
[Abstract only]
Epelbaum et al., 2000
77 20 (20) 12 20 50
[Abstract only]
Reyes-Vidal et al., 2000
78 14 (14) 43 14 43
[Abstract only]
Wilkowski et al., 2000
79 13
[Abstract only]
TABLE 22  Additional reports: gemcitabine and hormonal treatment
Reference                             No. entered                Median survival               PR (%)                   SD (%)                     CBR (%)
(evaluated)                    (months)              
Caillouette et al., 1999
80 19 (14) 4.5 7
[Abstract only]
Tomao et al., 1998
81 17 (17) 6 53 47
[Abstract only]Health Technology Assessment 2001; Vol. 5: No. 24
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Appendix 4
Tables 24–26
TABLE 24  Ongoing studies: RCTs
Title Interventions Expected Status
accrual
European study of pancreatic cancer – adjuvant chemotherapies in A = 5-FU/FA 990 Open
operable pancreatic cancer B = gemcitabine
C = surgery alone
Phase III study of adjuvant fluorouracil chemoradiation preceded and  A = chemoradiation + 5-FU 330 Open
followed by fluorouracil or gemcitabine in patients with resected  B = chemoradiation 
pancreatic adenocarcinoma and gemcitabine
Phase III randomised study of gemcitabine with or without 5-FU in  A = gemcitabine 320 Closed
patients with advanced pancreatic adenocarcinoma B = gemcitabine + 5-FU
Phase III randomised study of weekly intravenous P-30 protein plus  A = gemcitabine 150 Closed
daily oral tamoxifen vs. weekly intravenous gemcitabine for advanced  B = tamoxifen, P-30 protein
pancreatic cancer
Randomised, double blind, placebo controlled multicentre study of  A = gemcitabine +  172 Open
CI-994 capsules plus gemcitabine infusion versus placebo capsules  CI994 capsules
plus gemcitabine infusion in the treatment of patients with advanced  B = gemcitabine + 
pancreatic cancer placebo capsules
Phase III randomised study of gemcitabine with or without R115777  A = gemcitabine 660 Open
in patients with advanced pancreatic cancer B = gemcitabine + R115777
Phase III randomised study of oral nitrocamptothecin versus gemcitabine  A = oral nitrocamptothecin 994 Open
in chemotherapy naive patients with unresectable locally advanced or  B = gemcitabine
metastatic adenocarcinoma of the pancreas
Phase III randomised study of oral nitrocamptothecin versus most  A = oral nitrocamptothecin 400 Open
appropriate chemotherapy in patients with recurrent or refractory  B = other chemotherapy
adenocarcinoma of the pancreas
Phase III study of gemcitabine versus intensive pancreatic proteolytic  A = gemcitabine                        72–90 Open
enzyme therapy with ancillary nutritional support in patients with  B = pancreatic proteolytic 
Stage II, III or IV adenocarcinoma of the pancreas enzyme therapy
9331IL/0008 A = ZD9331 300 Open
B = gemcitabine
EMD 121974-004 A = gemcitabine + EMD 121974 60 Open
B = gemcitabine
TABLE 25  Ongoing studies: Phase II
Title Interventions Expected Status
accrual
Phase I/II study of concurrent prolonged gemcitabine infusion and  Gemcitabine and                       12–24 Closed
external beam radiation for the treatment of locally advanced  dose-escalation RT
pancreatic cancer
Phase II randomised study of gemcitabine vs. immunotherapy with  A = gemcitabine 150 Closed
cytoimplant as first line therapy in patients with unresectable, locally  B = cytoimplant
advanced or metastatic pancreatic cancer
Phase II randomised study of SCH 66336 versus gemcitabine in patients  A = gemcitabine 60 Closed
with metastatic adenocarcinoma of the pancreas  B = SCH 66336
continuedAppendix 4
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TABLE 25 contd  Ongoing studies: Phase II
Title Interventions Expected Status
accrual
Phase II study of cetuximab and gemcitabine in patients with locally  Cetuximab and gemcitabine 40 Closed
advanced, metastatic or recurrent adenocarcinoma of the pancreas
Phase II study of 5-FU, LV calcium and gemcitabine in patients with  5-FU, leucovorin and                   14–80 Closed
locally advanced or metastatic pancreatic adenocarcinoma gemcitabine
Phase II study of gemcitabine and docetaxel in patients with locally  Gemcitabine and docetaxel 33 Closed
advanced or metastatic adenocarcinoma of the pancreas
Phase II study of gemcitabine and doxorubicin in patients with  Gemcitabine and                       14–40 Closed
recurrent or refractory pancreatic cancer doxorubicin
Phase II study of gemcitabine combined with radiation therapy in  Gemcitabine and RT 40 Closed
patients with locoregional adenocarcinoma of the pancreas
Phase I/II study of gemcitabine and cisplatin followed by combined  Gemcitabine and CDDP        Phase I = 15–36 Open
chemoradiation and/or surgical resection in patients with locally  Phase II = 14–25
advanced pancreatic cancer
Phase I/II study of gemcitabine plus oxaliplatin in patients with refractory  Gemcitabine and                         20–40 Open
locally advanced or metastatic pancreatic carcinoma oxaliplatin
Phase II randomised study of docetaxel and gemcitabine versus docetaxel  A = docetaxel 82 Open
and cisplatin in metastatic or locoregionally advanced pancreatic carcinoma B = gemcitabine plus 
docetaxel
Phase II study of gemcitabine and oxilaplatin in patients with locally  Gemcitabine and oxaliplatin 66 Open
advanced or metastatic pancreatic carcinoma
Phase II study of gemcitabine and trastuzumab (herceptin) in patients  Gemcitabine and trastuzumab 41 Open
with metastatic pancreatic cancer and overexpression of HER2-Neuq
Phase II study of gemcitabine, cisplatin and fluorouracil in patients with  Gemcitabine, CDDP and 5-FU 30 Open
unresectable Stage III or IV pancreatic adenocarcinoma
A Phase II randomised study of an investigation of new medication  A = oral investigational medication NS NS
vs. intravenous 5-FU in patients with pancreatic cancer whose disease has  B = 5-FU
progressed following treatment with gemcitabine HCl treatment
A Phase II randomised study comparing the safety and efficacy of avicine  A = avicine NS NS
to avicine administered with gemcitabine in patients with pancreatic cancer B = avicine + gemcitabine
Gemcitabine and tomudex treatment in pancreatic cancer Gemcitabine and tomudex 40 Open
Phase I/II study to investigate the use of gemcitabine in combination with Gemcitabine and raltitrexed 30 Open
raltitrexed in locally advanced metastatic adenocarcinoma of the pancreas
A Phase I/II study of gemcitabine and escalating doses of cisplatin in patients  Gemcitabine and CDDP 44 Open
with inoperable pancreatic carcinoma
A randomised Phase II trial of neoadjuvant therapy for patients with  A = gemcitabine NS Open
resectable pancreatic cancer; gemcitabine alone versus gemcitabine  B = gemcitabine + CDDP
combined with cisplatin versus gemcitabine with radiotherapy C = gemcitabine + RT
Phase II study to evaluate the feasibility and efficacy of combining  Gemcitabine and flutamide           14–25 Open
gemcitabine with flutamide in advanced pancreatic cancer
A Phase II randomised open-label study of SCH 66336 and an active reference SCH 66336 and gemcitabine 30 Open
agent gemcitabine in patients with adenocarcinoma of the pancreas
A Phase II trial of gemcitabine, herceptin and radiation for regionally  Gemcitabine and herceptin NS  Open
confined adenocarcinoma of the pancreas
CDDP, cisplatin; NS, not statedHealth Technology Assessment 2001; Vol. 5: No. 24
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TABLE 26  Ongoing studies: design unclear from details available
Title Interventions Expected Status
accrual
Combination therapy in the treatment of patients with advanced  A = gemcitabine NS NS
pancreatic cancer B = gemcitabine + 
investigational oral medication
Study for patients with a histologic diagnosis of pancreatic cancer A = drug/gemcitabine NS NS
B = drug/placebo
Investigation medication for the treatment of advanced pancreatic cancer A = drug/gemcitabine NS NS
B = gemcitabineHealth Technology Assessment 2001; Vol. 5: No. 24
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Calculation of survival gains as 
the area between the curves
The area under a survival curve indicates the
overall survival time experienced by the cohort.
Therefore, the area between the gemcitabine and
5-FU curves indicates the difference in survival
experienced by the two groups (Figure 4). To
calculate the area accurately, data points needed 
to be extrapolated from the graphs. The Kaplan–
Meier product-limit estimator was used to estimate
the mean (Figure 5); this was then verified by using
the trapezoidal rule (Figure 6) to define errors.
In the first method, the mean survival time is
calculated by multiplying the difference in each
time step by the proportion of patients still alive.
Data points are extrapolated at each step.
In the second method, data points are extrapolated
from the graph at very small time steps. The area is
then calculated using the trapezoidal rule, a simple
numerical integration technique.
These methods were used to calculate the
difference in mean overall survival (months) 
and mean time to progression (months) for 
the gemcitabine and 5-FU curves. The results,
compared with the median values from the 
Burris trial,
13 are given in Tables 31 and 32.
Inter-rater reliability was within 1%, with no
difference according to the method used. Although
simple, these methods give a better indication of
the difference in the survival experience of the two
groups than a measure of the proportion surviving
to a given point or the median survival time.
Appendix 5
Derivation of area under the curve
5-FU
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Gemcitabine group
Area under the
curve indicates
the difference in
survival time
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FIGURE 4 Area under the curveAppendix 5
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FIGURE 5 Kaplan–Meier product limit estimator
FIGURE 6 Trapezoidal rule
k
Mean = ΣS(ti) × (ti+1) – ti) = S(t0) × (t1 – t0) + ... + S(tk) × (tk+1 – tk)
i=0
Where t = time and S = proportion of patients alive
h Mean = – [S0 + 2(S1 + S2 + ... + Sk–1)+ Sk]
2
Where h = step size and S = proportion of patients aliveHealth Technology Assessment 2001; Vol. 5: No. 24
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TABLE 31  Mean overall survival (months) for gemcitabine and
5-FU calculated by Kaplan–Meier and trapezoidal methods
Method 1: Method 2: Burris et al.,
Kaplan–Meier trapezoidal 1997
13 (median)
Gemcitabine 6.734 6.744 5.650
5-FU 4.345 4.351 4.410
TABLE 32  Mean time to progression (months) for gemcitabine
and 5-FU calculated by Kaplan–Meier and trapezoidal methods
Method 1: Method 2: Burris et al.,
Kaplan–Meier trapezoidal 1997
13 (median)
Gemcitabine 3.930 3.930 2.330
5-FU 2.083 2.099 0.920Health Technology Assessment 2001; Vol. 5: No. 24
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Q-TWiST methodology
The Q-TWiST method is a technique that has been
used frequently for evaluating survival in terms of
both duration and quality of life, particularly in
oncology. The method divides overall survival into
different health states. The components normally
used are: (1) survival time without symptoms and
without toxicity, denoted as TWiST; (2) survival
time with treatment-induced toxicity, denoted 
as TOX; and (3) survival after relapse, denoted as
REL. Therefore, overall survival = TWiST + 
TOX + REL.
If QoL has not been recorded in the trial, then the
TWiST component is usually characterised by a
normal level of QoL, or a utility score equal to 1.
Both TOX and REL correspond to a compromised
QoL and are therefore assigned a utility score
equal to 0.5.
In the article by Burris and colleagues,
13 the data
did not conform to the standard Q-TWiST health
states, so alternative progressive health states were
considered, which could be derived from the data
and were also clinically meaningful. Overall
survival graphs were given for patients receiving
both drugs and also corresponding time to
progression graphs. Within the article, clinical
benefit was reported as another end-point, stating
the percentage of patients achieving clinical
benefit and its median duration for patients in
both arms of the trial.
This gives three health states:
A: time in clinical benefit
B: time to disease progression when not in 
clinical benefit
C:time from disease progression to death.
The three health states for the gemcitabine arm
are shown in Figure 7 and those for the 5-FU arm 
in Figure 8.
Sensitivity analysis
Below are a series of scenarios relating to Table 33
when the utility scores for the different health
states are varied across feasible ranges.
• Scenario 1 is the default scenario.
• Scenario 2 shows the difference when the 
QoL is reduced at the time when the patient 
is experiencing clinical benefit (A).
• Scenarios 3–6 show the effect of increasing 
and decreasing the utility scores for time to
progression when not in clinical benefit (B) and
the time from disease progression to death (C).
•S cenarios 7–11 show variations in combinations
of health state utility scores.
•S cenarios 12–15 show variations in utility scores
between the different drug regimens.
Appendix 6
Use of Q-TWiST analysis
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FIGURE 7 The 3 health states in the gemcitabine arm
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FIGURE 8 The 3 health states in the 5-FU arm
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TABLE 33  Sensitivity analysis
Scenario Time in Time to disease Time from disease QALY Cost per
clinical benefit progression when progression gained QALY (£)
not in clinical benefit to death
1 1.0 0.5 0.5 0.148 21,088
2 0.7 0.5 0.5 0.116 26,952
3 1.0 0.7 0.5 0.150 20,804
4 1.0 0.3 0.5 0.146 21,379
5 1.0 0.5 0.6 0.155 20,119
6 1.0 0.5 0.1 0.120 26,115
7 1.0 0.7 0.6 0.157 19,861
8 1.0 0.7 0.1 0.122 25,682
9 1.0 0.3 0.6 0.153 20,384
10 1.0 0.3 0.1 0.118 26,563
11 0.7 0.3 0.1 0.085 36,593
12 0.196 15,960
Gemcitabine 1.0 0.7 0.5
5-FU 1.0 0.7 0.5
13 0.103 30,460
Gemcitabine 1.0 0.5 0.5
5-FU 1.0 0.5 0.5
14 0.194 16,126
Gemcitabine 1.0 0.5 0.5
5-FU 1.0 0.3 0.5
15 0.101 31,071
Gemcitabine 1.0 0.3 0.5
5-FU 1.0 0.5 0.5Health Technology Assessment 2001; Vol. 5: No. 24
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